EP1173415A1 - Diphenylurea derivatives - Google Patents

Diphenylurea derivatives

Info

Publication number
EP1173415A1
EP1173415A1 EP00920908A EP00920908A EP1173415A1 EP 1173415 A1 EP1173415 A1 EP 1173415A1 EP 00920908 A EP00920908 A EP 00920908A EP 00920908 A EP00920908 A EP 00920908A EP 1173415 A1 EP1173415 A1 EP 1173415A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
amino
formula
compound
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00920908A
Other languages
German (de)
French (fr)
Inventor
Keith Oldham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1173415A1 publication Critical patent/EP1173415A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Definitions

  • This invention relates to compounds which are inhibitors of the interaction between the integrin ⁇ 4 ⁇ , also known as Very Late Antigen-4 (VLA-4) or CD49d/CD29, and its protein ligands, for example Vascular Cell Adhesion Molecule- 1 (VCAM-1) and fibronectin.
  • VLA-4 Very Late Antigen-4
  • VCAM-1 Vascular Cell Adhesion Molecule- 1
  • fibronectin fibronectin.
  • This invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing them and to their use in methods of therapeutic application.
  • ⁇ 4 ⁇ is a member of the integrin family of heterodimeric cell surface receptors that are composed of noncovalently associated glycoprotein subunits ( ⁇ and ⁇ ) and are involved in cell adhesion to other cells or to extracellular matrix.
  • integrin ⁇ subunits There are at least 14 different human integrin ⁇ subunits and at least 8 different ⁇ subunits and each ⁇ subunit can form a heterodimer with one or more ⁇ subunits. Integrins can be subdivided based on their ⁇ subunit composition. ⁇ 4 ⁇ , is one of several ⁇ , integrins, also known as Very Late Antigens (VLA).
  • VLA Very Late Antigens
  • integrins The interactions between integrins and their protein ligands are fundamental for maintaining cell function, for example by tethering cells at a particular location, facilitating cell migration, or providing survival signals to cells from their environment.
  • Ligands recognised by integrins include extracellular matrix proteins, such as collagen and fibronectin; plasma proteins, such as fibrinogen; and cell surface molecules, such as transmembrane proteins of the immunoglobulin superfamily and cell-bound complement.
  • the specificity of the interaction between integrin and ligand is governed by the ⁇ and ⁇ subunit composition.
  • Integrin ⁇ 4 ⁇ is expressed on numerous hematopoietic cells and established cell lines, including hematopoietic precursors, peripheral and cytotoxic T lymphocytes, B lymphocytes, monocytes, thymocytes and eosinophils [Hemler, M.E. et al (1987), J. Biol. Chem., 262, 11478-11485; Bochner, B.S. et al (1991), J. Exp. Med., 173, 1553-1556].
  • integrins that bind only to cell-extracellular matrix proteins ⁇ 4 ⁇ , binds to VCAM-1, an immunoglobulin superfamily member expressed on the cell surface, for example on vascular endothelial cells, and to fibronectin containing the alternatively spliced type III connecting segment (CS-1 fibronectin) [Elices, M.J. et al (1990), Cell, 60, 577-584; Wayner, E.A. et al (1989). J. Cell Biol, 109, 1321-1330].
  • ⁇ 4 ⁇ is believed to have an important role in the recruitment of lymphocytes, monocytes and eosinophils during inflammation.
  • ⁇ 4 ⁇ /ligand binding has also been implicated in T-cell proliferation, B-cell localisation to germinal centres, haemopoeitic progenitor cell localisation in the bone marrow, placental development, muscle development and tumour cell metastasis.
  • ⁇ 4 ⁇ The affinity of ⁇ 4 ⁇ , for its ligands is normally low but chemokines expressed by inflamed vascular endothelium act via receptors on the leukocyte surface to upregulate ⁇ 4 ⁇ , function [Weber, C. et al (1996), J. Cell Biol, 134, 1063-1073].
  • VCAM-1 expression is upregulated on endothelial cells in vitro by inflammatory cytokines [Osborn. L. et al (1989) Cell, 59, 1203-121 1] and in human inflammatory diseases such as rheumatoid arthritis [Morales-Ducret, J. et al (1992). J.
  • Monoclonal antibodies directed against the ⁇ 4 integrin subunit have been shown to be effective in a number of animal models of human inflammatory diseases including multiple sclerosis, rheumatoid arthritis, allergic asthma, contact dermatitis, transplant rejection, insulin- dependent diabetes, inflammatory bowel disease, and glomerulonephritis.
  • Integrins recognise short peptide motifs in their ligands
  • the minimal ⁇ 4 ⁇ , binding epitope in CS-1 is the tripeptide leucine-aspartic acid-valine (Leu-Asp-Val) [ Komoriya, A., et al (1991). J. Biol. Chem., 266, 15075-15079] while VCAM-1 contains the similar sequence isoleucine-aspartic acid-serine [Clements, J.M., et al (1994). J. Cell Sci., 107, 2127-2135].
  • the 25-amino acid fibronectin fragment, CS-1 peptide, which contains the Leu Asp-Val motif, is a competitive inliibitor of 4 ⁇ , binding to VCAM-1 [Makarem, R., et al (1994). J. Biol. Chem., 269, 4005-4011].
  • Small molecule ⁇ 4 ⁇ , inhibitors based on the Leu- Asp-Val sequence in CS-1 have been described, for example the linear molecule phenylacetic acid-Leu-Asp-Phe-D-Pro-amide [Molossi, S. et al (1995). J. Clin.
  • a " is NH or NR 6 , where R 6 is C,. 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkanoyl or C,. 6 alkoxycarbonyl;
  • B is oxygen or sulphur
  • Y " is a linker group comprising an optionally substituted hydrocarbyl chain which is optionally interposed by one or more heteroatoms independently selected from oxygen, nitrogen and sulphur and/or by a monocyclic or bicyclic ring system; or linker group Y and
  • A' can be taken together to form a 5 to 7 membered heterocyclic ring, optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,. 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C,. 6 alkoxy, C 2 _
  • R' and R 4 are each independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,_ 6 alkyl, C 2 . 6 alkenyl,
  • R a and R b are independently hydrogen or C,_ 6 alkyl or one of R 4 can be taken together with A' to form a 5 to 7 membered heterocyclic ring optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,. 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C,. 6 alkoxy,
  • R 2 and R 3 are each independently selected from hydrogen, C,. 6 alkyl, C,- 3 alkanoyl or
  • R 5 is an acidic functional group; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof.
  • hydrocarbyl chain refers to an alkylene, alkenylene and alkynylene group, for example of from 1 to 10 carbon atoms in the case of the alkylene group and from 2 to 10 carbon atoms in the case of alkenylene and alkynylene groups which may be optionally interposed with one or more of the groups listed above.
  • the linker group is an alkylene chain which is interposed by a monocyclic ring system and optionally also at least one heteroatom.
  • the ring system is preferably a monocyclic ring system as defined hereinafter.
  • Suitable substitutents for the linker group Y' include any of the groups listed above for R 1 and R 4 as well as aryl groups such as phenyl or naphthyl or aralkyl groups such as benzyl.
  • the substituents include C,. 6 alkyl, C 2 . 6 alkenyl, C 2.6 alkynyl, aryl such as phenyl and aralkyl such as benzyl.
  • substitutents may be present on said atom.
  • the linker group is such that the spacing of the group B and the group R 5 by not more than 10 atoms.
  • a basic group, and in particular a moiety containing at least one nitrogen is present within linker Y' .
  • the group A' is orientated in the meta or para position with respect to the ureido group in formula (I), and most preferably A' is orientated para- to the ureido group in formula (I).
  • the invention comprises a compound of formula (IA)
  • A is nitrogen or NR 6 , where R 6 is C,. 6 alkyl, C 2 . 6 alkanoyl or C ⁇ alkoxycarbonyl;
  • B is oxygen or sulphur
  • Y is a linker group connecting group B to group R 5 and containing up to 10 atoms where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and may optionally comprise a monocyclic or bicyclic ring system or linker group Y and A can be taken together to form a 5 to 7 membered heterocyclic ring, optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,. 6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C,. 6 alkoxy, C 2 . 6 alkenyloxy, C 2 .
  • R 1 and R 4 are each independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,. 6 alkyl, C 2 . 6 alkenyl,
  • R a and R b are independently hydrogen or C,. 6 alkyl or one of R 4 can be taken together with A to form a 5 to 7 membered heterocyclic ring optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,. 5 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C,_ 6 alkoxy,
  • R 2 and R 3 are each independently selected from hydrogen, C,. 6 alkyl, C,- 3 alkanoyl or
  • R 5 is an acidic functional group; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof.
  • Y or Y' preferably excludes those linker groups which are unstable in acid conditions such as those found in the stomach of a human or animal body, for example
  • the 5 to 7 heterocyclic can be an, optionally substituted, saturated or unsaturated ring with up to three heteroatoms independently selected from nitrogen, oxygen and sulphur.
  • An example of such a ring is an oxazolidinone, oxazolone and thiazolone.
  • Linker group Y or Y' can comprise a monocyclic ring or a bicyclic ring.
  • 'monocyclic ring' means a 5 to 7 membered ring. It can be an, optionally substituted, preferably aromatic ring with up to three heteroatoms independently selected from nitrogen, oxygen and sulphur. Examples of such rings include phenyl, pyrimidinyl, pyridyl, imidazolyl, thienyl, thiazolyl, pyridazinyl and pyrrolyl. Other examples include morpholino, tetrahydropyridyl or tetrahydropyrazolyl.
  • 'bicyclic ring system' means an 8 to 10 membered fused ring system wherein one or both rings may contain ring heteroatoms.
  • the ring system may be totally or partially saturated, optionally substituted and contain up to five heteroatoms independently selected from oxygen, nitrogen or sulphur.
  • suitable ring systems include naphthalene, quinazoline, benzothiophene, benzoxazole, benzothiazole, and benzofuran and the corresponding hydro derivatives, e.g. tetrahydronaphthalene and dihydroquinazoline .
  • 'acidic functional group' means a group which incorporates an acidic hydrogen and includes carboxylic acids, tetrazoles, acyl sulphonamides, sulphonic and sulphinic acids.
  • the group Y' or Y is the group
  • A, B, R 1 to R 5 , m and n are as hereinbefore defined;
  • D and G are each independently C,_ 4 alkyl or C 2 . 4 alkenyl and each carbon is optionally substituted with halogeno, hydroxy, amino, nitro, phenyl, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,. 6 alkyl, C 2 . 6 alkenyl, C,. 6 alkanoyl, C 2 . 6 alkynyl, C,. 5 alkoxy,
  • E is phenyl or a monocyclic heterocycle both optionally substituted with up to 3 substituents selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C, .6 alkyl, C 2 . 6 alkenyl, C 2 . 6 alkynyl, C,. 6 alkoxy, C 2 . 6 alkenyloxy,
  • R 9 and R 10 are independently hydrogen or C,. 6 alkyl or E and D can be taken together to form a bicyclic ring system, optionally substituted with up to 3 substituents selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,. 6 alkyl, C 2 . 6 alkenyl, C 2 _
  • F is selected from oxygen, sulphur, amino or CR n R 12 ; p and q are each independently 0 or 1 ; R" and R 12 are each independently selected from hydrogen, halogeno, hydroxy, amino, nitro, phenyl, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,. 6 alkyl, C 2.6 alkenyl, C,. 6 alkanoyl, C 2 . 6 alkynyl, C,. 6 alkoxy, C 2 . 6 alkenyloxy, C 2 . 6 alkynyloxy, C,_ 6 alkylamino, di-[(C,. 6 )alkyl]amino, C,.
  • the 5 to 7 membered ring that can be formed by taking together A and D is a heterocycle ring. It can be an, optionally substituted, saturated or unsaturated ring with up to three heteroatoms independently selected from nitrogen, oxygen and sulphur.
  • An example of such a ring is an oxazolidinone, oxazolone and thiazolone.
  • 'monocyclic heterocycle means a 5 to 7 membered ring. It can be an, optionally substituted, preferably aromatic ring with up to three heteroatoms independently selected from nitrogen, oxygen and sulphur. Examples of such rings include pyrimidinyl, pyridyl, imidazolyl, thienyl, thiazolyl, pyridazinyl and pyrrolyl.
  • the "monocyclic heterocycle” is a non-aromatic heterocyclic ring.
  • the rings are linked either to the groups D and/or F by means of a nitrogen atom.
  • groups include morpholino, tetrahydropyridyl or tetrahydropyrazolyl.
  • 'bicyclic ring system means an 8 to 10 membered fused ring system wherein one or both rings may contain ring heteroatoms.
  • the ring system may be totally or partially saturated, optionally substituted and contain up to five heteroatoms. independently selected from oxygen, nitrogen or sulphur.
  • suitable ring systems include naphthalene, quinazoline, benzothiophene, benzoxazole, benzothiazole, and benzofuran and the corresponding hydro derivatives, e.g. tetrahydronaphthalene and dihydroquinazoline.
  • 'acidic functional group' means a group which incorporates an acidic hydrogen and includes carboxylic acids, tetrazoles, acyl sulphonamides, sulphonic and sulphinic acids.
  • Particularly preferred values for E in formula (II) is phenyl.
  • Groups D and F are preferably arranged in the ortho- or meta- positions on phenyl ring E, and most preferably are orientated meta- to each other.
  • E is a monocyclic heterocycle as defined above, and in particular is an N-linked 6 membered non-aromatic heterocycle.
  • A' in formula (I) is NH or NR 6 where R 6 is C,. 6 alkyl such as methyl or C 2 _ 6 alkenyl such as ethen-2-yl. More preferably A' (or A in Formula (IA) and (II)) is NH or NCH 3 and most preferably A or A' is NH.
  • R 1 is a C,. 6 alkyl group such as methyl, which is in the ortho position on the phenyl ring relative to the ureido group.
  • m is 1.
  • R 2 and R 3 are hydrogen or C,_ 4 alkyl and most preferably are both hydrogen.
  • a particular preferred value for B is oxygen.
  • R 4 include C ⁇ alkyl such as methyl, or C,_ 6 alkoxy such as methoxy.
  • n is suitably 0, 1 or 2.
  • a particularly preferred group of compounds of formula (I) are those of formula (III)
  • R', R 2 , R 3 , A, B, Y, R 5 and m are as defined above and R 4a is either hydrogen or C,_ 6 alkoxy such as methoxy, and R 4b is either hydrogen or C,. 6 alkyl such as methyl.
  • a preferred value for F in formula (II) is oxygen.
  • R 5 is carboxy
  • Suitable values for R 1 to R ⁇ R 6 , R 1 ' to R 16 and for various substituents on Y(or Y'), D, E, F, G or on any ring formed between Yor Y' and A or A', A or A' and D, D and E, A or A' and R 4 include :- or halogeno: fluoro, chloro, bromo and iodo or C,.
  • 6 alkyl methyl, ethyl, propyl, isopropyl and tert-butyl; or C 2 .
  • 6 alkenyl vinyl, allyl and but-2-enyl; or C,.
  • 6 alkylamino dimethylamino, diethylamino; for C 2 . 6 alkanoylamino: acetamido, propionamido and butyramido; for N-C,. 6 alkylcarbamoyl: N-methylcarbamoyl, N-ethylcarbamoyl and N-propylcarbamoyl; for N,N-di-C alkylcarbamoyl: N,N-dimethylcarbamoyl,
  • Particularly suitable compounds of formula (II) or pharmaceutically acceptable salts thereof include are those wherein, unless otherwise stated each of R 1 to R 16 , A, B, D to G, m, p to u has any of the meanings defined hereinbefore or below in sections a to h a) B is oxygen, D and G are each independently a C alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen and R 5 is carboxy.
  • B is oxygen, D and G are each independently a C alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen and is in the meta position with respect to E and R 5 is carboxy.
  • B is oxygen, D and G are each independently a C alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen, R 5 is carboxy and R 1 and R 4 are each independently C,. 6 alkyl or C,. 6 alkoxy.
  • B is oxygen, D and G are each independently a C M alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen, R 5 is carboxy, R 1 and R 4 are each independently C,.
  • B is oxygen
  • D and G are each independently a C,. 4 alkyl, optionally substituted as hereinbefore defined
  • E is phenyl
  • F is oxygen
  • R 5 is carboxy
  • R 2 and R 3 are each independently C 6 alkyl, preferably methyl.
  • B is oxygen
  • D and G are each independently a C M alkyl, optionally substituted as hereinbefore defined
  • E is phenyl
  • F is oxygen
  • R 5 is carboxy and
  • R 6 is C
  • B is oxygen
  • D is a C M alkyl, optionally substituted as hereinbefore defined
  • E is phenyl
  • q is zero
  • G is a C alkyl or C alkenyl, optionally substituted as hereinbefore defined and R 3 is carboxy.
  • B is oxygen
  • D and G are each independently C,_ 4 alkyl, optionally substituted as hereinbefore defined
  • E is phenyl
  • F is oxygen
  • B is oxygen
  • D and G are each independently a C,. 4 alkyl, optionally substituted as hereinbefore defined
  • q is 1
  • E is morpholino which is N-linked to the group G and is linked to D at the 2 position on the morpholine ring
  • R 5 is carboxy.
  • B is oxygen, D and G are each independently a C M alkyl, optionally substituted as hereinbefore defined, q is 0, E is tetrahydropyridyl which is N-linked to the group G and is linked to D at the 4 position on the ring, and R 5 is carboxy;
  • B is oxygen, D and G are each independently a C,_ 4 alkyl, optionally substituted as hereinbefore defined, q is 0, E is tetrahydropyridyl which is N-linked to the group D and is linked to G at the 4 position on the ring, and R 5 is carboxy;
  • B is oxygen, D and G are each independently a C alkyl, optionally substituted as hereinbefore defined, q is 0, E is tetrahydropyridyl which is N-linked to the group G and is linked to D at the 2 position on the ring, and R 5 is carboxy;
  • B is oxygen, D and G are each independently a C,_ 4 alkyl, optionally substituted as hereinbefore defined, q is 0, E is tetrahydropyrazinyl which is N-linked to the group D and G, and R 5 is carboxy.
  • salts include acid addition salts such as salts formed with mineral acids, for example, hydrogen halides such as hydrogen chloride and hydrogen bromide, sulphonic and phosphonic acids; and salts formed with organic acids, especially citric, maleic, acetic, oxalic, tartaric, mandelic, p-toluenesulphonic, methanesulphonic acids and the like.
  • suitable salts are base salts such as alkali metals salts, for example, sodium and potassium; alkaline earth metal salts such as magnesium and calcium; aluminium and ammonium salts; and salts with organic bases such as ethanolamine, methylamine, diethylamine, isopropylamine, trimethylamine and the like.
  • Such salts may be prepared by any suitable method known in the art.
  • In vivo hydrolysable derivatives include, in particular, pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, for example, intravenously to the test animal, the compound under test and subsequently examining the test animal's body fluids.
  • Suitable in vivo hydrolysable esters for hydroxy include acetyl and for carboxy include, for example, alkyl esters, dialkylaminoalkoxy esters and C,. 6 alkoxy methyl esters for example methoxymethyl, C -alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3 . 8 cycloalkoxycarbonyloxyC,.
  • 6 alkyl esters for example 1 -cyclohexylcarbonyloxy ethyl; l,3-dioxolan-2-ylmethyl esters for example 5-methyl-l,3-dioxolan-2-ylmethyl; and C,. 6 alkoxycarbonyloxy ethyl esters for example 1-methoxycarbonyloxyethyl.
  • optically active or racemic forms by virtue of one or more asymmetric carbon atoms
  • the invention includes in its definition any such optically active or racemic form which possesses the property of inhibiting the interaction between VCAM-1 and fibronectin with integrin ⁇ 4 ⁇ ,.
  • the synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art. These include, for example, synthesis from optically active starting materials or by resolution of a racemic form.
  • VCAM-1 and fibronectin with integrin ⁇ 4 ⁇ i may be determined using a number of in vitro and in vivo screens, as hereinafter defined.
  • compounds of formula (I) preferably have an IC 50 of ⁇ 10 ⁇ M, more preferably ⁇ l ⁇ M in the MOLT-4 cell/Fibronectin assay hereinafter described.
  • a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof is typically formulated as a pharmaceutical composition in accordance with standard pharmaceutical practice.
  • a pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions of this invention may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example as a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension, or a depot formulation with drug incorporated in a biodegradable polymer.
  • compositions of this invention may be in a form suitable for topical administration such as for example creams, ointments and gels. Skin patches are also contemplated.
  • compositions of this invention may be formulated by means known in the art, such as for example, as described in general terms, in Chapter 25.2 of Comprehensive Medicinal Chemistry, Volume 5, Editor Hansch et al, Pergamon Press 1990.
  • the pharmaceutical composition of the present invention may contain one or more additional pharmacological agents suitable for treating one or more disease conditions referred to hereinabove in addition to the compounds of the present invention.
  • the additional pharmacological agent or agents may be co-administered, either simultaneously or sequentially, with the pharmaceutical compositions of the invention.
  • composition of the invention will normally be administered to humans such that the daily dose will be 0.01 to 75mg/kg body weight and preferably 0.1 to 15mg/kg body weight.
  • a preferred composition of the invention is one suitable for oral administration in unit dosage form for example a tablet or capsule which contains from 1 to 1 OOOmg and preferably 10 to 500mg of a compound according to the present invention in each unit dose.
  • a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof for use in a method of therapeutic treatment of the human or animal body.
  • the present invention provides a method of treating a disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor ⁇ 4 ⁇ , in need of such treatment which comprises administering to said warm-blooded mammals an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof.
  • the present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof in the production of a medicament for use in the treatment of a disease or medical condition mediated by the interaction between fibronectin and/or VCAM-1 (especially VCAM-1) and the integrin receptor ⁇ 4 ⁇ ,
  • the mammal in need of treatment is suffering from multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease, psoriasis, atherosclerosis, transplant rejection, inflammatory bowel disease, insulin-dependent diabetes and glomerulonephritis.
  • Preferred compounds of formula (I) for use in these various embodiments of the invention are as set out above and include compounds of formula (IA) or (II).
  • a process for preparing a compound of formula (I), a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof which method comprises either (a) reacting a compound of formula (IV)
  • a ⁇ R 1 , R 2 , R ⁇ R 4 , m and n are as defined in relation to formula (I), with a compound of formula (V) where B and Y' are as defined in relation to formula (I), Z is a leaving group, such as halo, and R' 7 is a group R 3 as defined in relation to formula (I) or a protected form thereof: or
  • R' and m are as defined in relation to formula (I); and thereafter if desired or necessary, i) removing any protecting groups; and ii) optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable derivative.
  • R 17 are ester groups an in particular C,. 6 alkyl esters.
  • Starting materials for the process may be obtained by standard organic chemistry procedures. The preparation of such starting materials is described in the following representative processes in conjunction with the accompanying Examples. Alternative starting materials are obtaintable by procedures which are analogous to those desctibed below and within the ordinary skill of an organic chemist.
  • One process (a) above comprises coupling together a compound of formula (IV) and (V) above, via the formation of a urethane or a carbamosulfanyl. The compounds are suitably reacted together in the presence of an inert solvent and in basic conditions.
  • a suitable solvent system for the aforementioned process is dichloromethane or tetrahydrofuran (THF) in the presence of pyridine.
  • a particular compound of formula (V) is a compound of formula (VIII)
  • Y is the group - D - (E) p - (F) q - G - and where B, D, E, F, G, p and q are as hereinbefore defined and R 17 is a COOC, .6 alkyl.
  • a particular example of a compound of formula (IV) is a compound of formula (IX)
  • R 1 , R 2 , R 3 , R 4 , n and m are as defined in relation to formula (I).
  • Such a compound can be prepared from the corresponding 3-methoxy-4(N'-(2- methylphenyl)urea)nitrobenzene.
  • the latter can be prepared from the reaction of the corresponding methoxy-nitroaniline together with methylphenylisocyanate.
  • Protecting groups may typically be chosen from any of the groups described in literature or known to the skilled person.
  • Suitable protecting groups for an amino group include for example, formyl, and alkoxycarbonyl groups, for example tert-butoxycarbonyl.
  • Suitable protecting groups for a hydroxy group include lower alkyl groups, for example tert-butyl, and acyl groups, for example an alkanoyl group such as acetyl.
  • Suitable protecting groups for a carboxy group include, an esterifying group, for example a methyl or ethyl group. These groups may be removed by any convenient method described in the literature or known to the skilled person for removal of the specific protection group in question. The method of removal is chosen so as to minimise disturbance on the other groups in the molecule.
  • the protecting group is an acyl group or a C,_ 2 alkyl group it may be removed by hydrolysis with a suitable base such as, for example, sodium hydroxide.
  • a tert-butyl protecting group may be removed with, for example, an organic acid such as trifluoroacetic acid .
  • An alternative method of preparing a compound of formula (I), a pharmaceutically acceptable salt or an in vivo hydrolysable derivative comprises reacting together a compound of formula (VI) and (VII), to form a urea linkage.
  • the reaction is suitably effected in the presence of an inert solvent.
  • Suitable inerts solvents for the aforementioned process include dichloromethane, THF or ethyl acetate.
  • any functional group is protected if necessary and i) removing any protecting groups; and ii) optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable derivative.
  • a particular example of a compound of formula (VI) is a compound of formula (XI)
  • A', Y', B, R 17 , R 4 and n are as defined above.
  • a suitable reduction regime would be iron powder in the presence of ammonium chloride/water/methanol .
  • nitroaniline derivative of formula (XVI) where A' is NH can be prepared by reacting an appropriate compound of formula (XIV)
  • reaction is suitably effected in an organic solvent such as dichloromethane of tetrahydrofuran (THF) in the present of a base such as triethylamine.
  • organic solvent such as dichloromethane of tetrahydrofuran (THF)
  • base such as triethylamine
  • Inert solvent e.g dichloromethane or THF + small amt. base e,g triethylamine
  • Example 1 Preparation of 4-(3-([( ⁇ 4-[(2-toIuidinocarbony ⁇ )amino]anilino ⁇ carbonyl)oxy]methvUphenoxy)butanoic acid (Compound No. 1 in Table 1)
  • IH nmr (DMSO-d6) included the following resonances : 2.0 (m), 2H; 2.2 (s), 3H; 2.5 (m), 2H; 3.6 (s), 3H; 3.8 (s), 3H; 4.0 (t), 2H; 5.1 (s), 2H;
  • the nitro compound from (b) (0.47g) was dissolved in ethanol (10 ml) and ammonium formate (0.625g; 10 equivalents) was added.
  • the reaction flask was flushed with argon, and the catalyst (10% Pd/C, 0.047mg; 0.1 equivalents by weight) was then added.
  • the reaction was heated to reflux and stirred at this temperature for 1 hour.
  • the reaction mixture was then cooled and filtered through a bed of celite, washing through with more ethanol.
  • the solvent was removed under reduced pressure, and the residue dissolved in ethyl acetate (50ml). This solution was then washed with water, brine, dried over anhydrous magnesium sulphate and concentrated under reduced pressure to give the above aniline as a brown oil (0.43g; 98% yield).
  • the compound No. refers to the Compound of formula (I) which was ultimately derived from the intermediate.
  • the compounds of the invention or pharmaceutically acceptable salts thereof may be formulated into tablets together with, for example, lactose Ph.Eur, Croscarmellose sodium, maize starch paste (5% w/v paste) and magnesium stearate for therapeutic or prophylactic use in humans.
  • the tablets may be prepared by conventional procedures well known in the pharmaceutical art and may be film coated with typical coating materials such as hydroxypropylmethylcellulose.
  • MOLT-4 cells human T-lymphoblastic leukaemia cells (European Collection of Animal Cell Cultures, Porton Down).
  • Fibronectin - purified from human plasma by gelatin-sepharose affinity chromatography according to the methods described in E.Nengvall, E.Ruoslahti, Int. J. Cancer, 1977, 20, pages 1-5 and J. Forsyth et al, Methods in Enzymology, 1992, 215, pages 31 1-316).
  • RPMI 1640 - cell culture medium (Life technologies, Paisley UK). PBS - Dulbecco's phosphate buffered saline (Life Technologies). BSA - Bovine serum albumin, fraction V (ICN, Thame, UK). CFA - Complete Freund's Adjuvant (Life Technologies).
  • the MOLT-4 cell /fibronectinadhesion assay was used to investigate the interaction of the integrin ⁇ 4 - ⁇ , expressed on the MOLT-4 cell membrane with fibronectin.
  • Polystyrene 96 well plates were coated overnight at 4°C with fibronectin, 100 ⁇ l of 10 ⁇ g/ml in PBS. Nonspecific adhesion sites were blocked by adding 100 ⁇ l BSA, 20 mg/ml. After incubating for 1 h at room temperature, the solutions were aspirated.
  • MOLT-4 cells suspended in serum-free RPMI-1640 medium 2E6 cells/ml (50 ⁇ l) and solutions of compound diluted in the same medium (50 ⁇ l) were added to each well.
  • mice (20-25g) are immunised on the flank with an 1 : 1 (v/v) emulsion of ovalbumin (2 mg/ml) with CFA. Seven days later the mice are challenged by subplantar injection of 1% heat aggregated ovalbumin in saline (30 ⁇ l) into the right hind foot pad. Swelling of the foot develops over a 24 hour period following which foot pad thickness is measured and compared with the thickness of the contralateral uninjected foot. The percentage increase in foot pad thickness is calculated. Compounds are dosed orally by gavage to groups of 5 mice at doses ranging from 0.001 mg/kg to 100 mg/kg. Inhibition of the inflammatory response is calculated comparing vehicle treated animals and compound treated groups. 1.2.2. Collagen-induced arthritis in mice
  • mice are immunised with 0.1ml of an emulsion prepared from equal volumes of bovine collagen type II in 0.05M acetic acid (2 mg/ml) and CFA. This mixture is injected at the base of the tail. Twenty days later compounds are dosed orally by gavage at doses ranging from O.OOlmg/kg/day to 100 mg/kg/day. On the day following the first dose, each animal receives an intra-peritoneal booster injection of 0.1ml of collagen type II in acetic acid. The mice are assessed for the incidence and severity of arthritis in all four limbs for up to 28 days. Inhibition of arthritis is calculated by comparing vehicle treated and compound treated mice.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A compound of formula (I) wherein A' is NH or NR6, where R6 is C¿1-6?alkyl, C2-6alkenyl, C2-6alkanoyl or C1-6alkoxycarbonyl; B is oxygen or sulphur; Y' is a specified linker group; m is from 0 to 5; n is from 0 to 4; R?1 and R4¿ are each independently selected from specified organic groups; and R5 is an acidic functional group; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof. These compounds are useful in the treatment of a disease or medical condition mediated by the interaction between fibronectin and/or VCAM-1 (especially VCAM-1) and the integrin receptor α¿4?β1.

Description

DEPHENYLUREA DERIVAΗVES
This invention relates to compounds which are inhibitors of the interaction between the integrin α4β,, also known as Very Late Antigen-4 (VLA-4) or CD49d/CD29, and its protein ligands, for example Vascular Cell Adhesion Molecule- 1 (VCAM-1) and fibronectin. This invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing them and to their use in methods of therapeutic application. α4β, is a member of the integrin family of heterodimeric cell surface receptors that are composed of noncovalently associated glycoprotein subunits (α and β) and are involved in cell adhesion to other cells or to extracellular matrix. There are at least 14 different human integrin α subunits and at least 8 different β subunits and each β subunit can form a heterodimer with one or more α subunits. Integrins can be subdivided based on their β subunit composition. α4β, is one of several β, integrins, also known as Very Late Antigens (VLA).
The interactions between integrins and their protein ligands are fundamental for maintaining cell function, for example by tethering cells at a particular location, facilitating cell migration, or providing survival signals to cells from their environment. Ligands recognised by integrins include extracellular matrix proteins, such as collagen and fibronectin; plasma proteins, such as fibrinogen; and cell surface molecules, such as transmembrane proteins of the immunoglobulin superfamily and cell-bound complement. The specificity of the interaction between integrin and ligand is governed by the α and β subunit composition.
Integrin α4β, is expressed on numerous hematopoietic cells and established cell lines, including hematopoietic precursors, peripheral and cytotoxic T lymphocytes, B lymphocytes, monocytes, thymocytes and eosinophils [Hemler, M.E. et al (1987), J. Biol. Chem., 262, 11478-11485; Bochner, B.S. et al (1991), J. Exp. Med., 173, 1553-1556]. Unlike other β, integrins that bind only to cell-extracellular matrix proteins, α4β, binds to VCAM-1, an immunoglobulin superfamily member expressed on the cell surface, for example on vascular endothelial cells, and to fibronectin containing the alternatively spliced type III connecting segment (CS-1 fibronectin) [Elices, M.J. et al (1990), Cell, 60, 577-584; Wayner, E.A. et al (1989). J. Cell Biol, 109, 1321-1330].
The activation and extravasation of blood leukocytes plays a major role in the development and progression of inflammatory diseases. Cell adhesion to the vascular endothelium is required before cells migrate from the blood into inflamed tissue and is mediated by specific interactions between cell adhesion molecules on the surface of vascular endothelial cells and circulating leukocytes [Sharar, S.R. et al (1995). Springer Semin. Immunopathol, 16, 359-378]. α4β, is believed to have an important role in the recruitment of lymphocytes, monocytes and eosinophils during inflammation. α4β, /ligand binding has also been implicated in T-cell proliferation, B-cell localisation to germinal centres, haemopoeitic progenitor cell localisation in the bone marrow, placental development, muscle development and tumour cell metastasis.
The affinity of α4β, for its ligands is normally low but chemokines expressed by inflamed vascular endothelium act via receptors on the leukocyte surface to upregulate α4β, function [Weber, C. et al (1996), J. Cell Biol, 134, 1063-1073]. VCAM-1 expression is upregulated on endothelial cells in vitro by inflammatory cytokines [Osborn. L. et al (1989) Cell, 59, 1203-121 1] and in human inflammatory diseases such as rheumatoid arthritis [Morales-Ducret, J. et al (1992). J. Immunol., 149, 1424-1431], multiple sclerosis [Cannella, B. et al., (1995). Ann. Neural., 37, 424-435], allergic asthma [Fukuda, T. et al (1996), Am. J. Respir. Cell Mol. Biol., 14, 84-94] and atherosclerosis [O'Brien, K.D. et al (1993). J. Clin. Invest, 92, 945-951].
Monoclonal antibodies directed against the α4 integrin subunit have been shown to be effective in a number of animal models of human inflammatory diseases including multiple sclerosis, rheumatoid arthritis, allergic asthma, contact dermatitis, transplant rejection, insulin- dependent diabetes, inflammatory bowel disease, and glomerulonephritis.
Integrins recognise short peptide motifs in their ligands The minimal α4β, binding epitope in CS-1 is the tripeptide leucine-aspartic acid-valine (Leu-Asp-Val) [Komoriya, A., et al (1991). J. Biol. Chem., 266, 15075-15079] while VCAM-1 contains the similar sequence isoleucine-aspartic acid-serine [Clements, J.M., et al (1994). J. Cell Sci., 107, 2127-2135]. The 25-amino acid fibronectin fragment, CS-1 peptide, which contains the Leu Asp-Val motif, is a competitive inliibitor of 4β, binding to VCAM-1 [Makarem, R., et al (1994). J. Biol. Chem., 269, 4005-4011]. Small molecule α4β, inhibitors based on the Leu- Asp-Val sequence in CS-1 have been described, for example the linear molecule phenylacetic acid-Leu-Asp-Phe-D-Pro-amide [Molossi, S. et al (1995). J. Clin. Invest., 95, 2601-2610] and the disulphide cyclic peptide Cys-Trp-Leu-Asp-Val-Cys [Vanderslice, P., et al (1997). J. Immunol.. 158, 1710-1718]. More recently, non- and semi-peptidic compounds which inhibit α4β,/VCAM binding and which can be orally administered have been reported in for example, WO96/22966 and WO98/04247.
There remains a continuing need for alternative compounds which inhibit the interaction between VCAM-1 and fibronectin with integrin α4β, and, in particular, for compounds which can be administered by an oral route.
We have now found a group of compounds which contain a urethane or carbamosulfanyl linkage which inhibits this interaction.
Accordingly the present invention provides a compound of formula (I)
wherein
A" is NH or NR6, where R6 is C,.6alkyl, C2.6alkenyl, C2.6alkanoyl or C,.6alkoxycarbonyl;
B is oxygen or sulphur;
Y" is a linker group comprising an optionally substituted hydrocarbyl chain which is optionally interposed by one or more heteroatoms independently selected from oxygen, nitrogen and sulphur and/or by a monocyclic or bicyclic ring system; or linker group Y and
A' can be taken together to form a 5 to 7 membered heterocyclic ring, optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C2_
()alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C,.6 alkyl]amino and C2.6alkanoylamino; m is from 0 to 5; n is from 0 to 4;
R' and R4 are each independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,_6alkyl, C2.6alkenyl,
C,.6alkanoyl, C2.6alkynyl, C,„6 alkoxy, C2.6alkenyloxy, C,.6alkynyloxy, C,_6 alkylamino, di-[(C,.6)alkyl]amino, C2.6alkanoylamino, N-C,.6alkylcarbamoyl, Cι_6alkoxylcarbonyl,
N,N-di-[(C,.6alkyl]carbamoyl, CMalkoxylC,.6alkyl, (CH2)tOH where t is 1 or 2,
-CO2Ra and CONRaR° where Ra and Rb are independently hydrogen or C,_6 alkyl or one of R4 can be taken together with A' to form a 5 to 7 membered heterocyclic ring optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy,
C2.6alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C,.6 alkyljamino and C2.6alkanoylamino;
R2 and R3 are each independently selected from hydrogen, C,.6 alkyl, C,-3 alkanoyl or
C|.6 alkoxycarbonyl; and
R5 is an acidic functional group; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof.
As used herein, the term "hydrocarbyl chain" as used in relation to linker Y' refers to an alkylene, alkenylene and alkynylene group, for example of from 1 to 10 carbon atoms in the case of the alkylene group and from 2 to 10 carbon atoms in the case of alkenylene and alkynylene groups which may be optionally interposed with one or more of the groups listed above.
In particular, the linker group is an alkylene chain which is interposed by a monocyclic ring system and optionally also at least one heteroatom. The ring system is preferably a monocyclic ring system as defined hereinafter.
Suitable substitutents for the linker group Y' include any of the groups listed above for R1 and R4 as well as aryl groups such as phenyl or naphthyl or aralkyl groups such as benzyl. In particular, the substituents include C,.6alkyl, C2.6alkenyl, C2.6alkynyl, aryl such as phenyl and aralkyl such as benzyl. Where the linker group Y' includes a nitrogen heteroatom, substitutents may be present on said atom.
Suitably, the linker group is such that the spacing of the group B and the group R5 by not more than 10 atoms.
In a preferred embodiment, a basic group, and in particular a moiety containing at least one nitrogen is present within linker Y' .
Preferably, the group A' is orientated in the meta or para position with respect to the ureido group in formula (I), and most preferably A' is orientated para- to the ureido group in formula (I).
In a particular embodiment, the invention comprises a compound of formula (IA)
wherein
A is nitrogen or NR6, where R6 is C,.6alkyl, C2.6alkanoyl or C^alkoxycarbonyl;
B is oxygen or sulphur;
Y is a linker group connecting group B to group R5 and containing up to 10 atoms where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and may optionally comprise a monocyclic or bicyclic ring system or linker group Y and A can be taken together to form a 5 to 7 membered heterocyclic ring, optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.
6alkynyloxy, C,.6alkylamino, di-[C|_6 alkyljamino and C2.6alkanoylamino; m is from 0 to 5; n is from 0 to 4;
R1 and R4 are each independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl,
C,.6alkanoyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C 6 alkylamino, di-[(C,.6)alkyl]amino, C2.6alkanoylamino, N-C:.6alkylcarbamoyl, C,.6alkoxylcarbonyl,
N,N-di-[(Cl.6alkyl]carbamoyl, C,.4alkoxylC,.6alkyl, (CH2)tOH where t is 1 or 2,
-CO,Ra and CONRaRb where Ra and Rb are independently hydrogen or C,.6 alkyl or one of R4 can be taken together with A to form a 5 to 7 membered heterocyclic ring optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.5alkyl, C2.6alkenyl, C2.6alkynyl, C,_6alkoxy,
C2.6alkenyloxy, C2.6alkynyloxy, C ^alkylamino, di-[C,.6 alkyl]amino and C2.6alkanoylamino;
R2 and R3 are each independently selected from hydrogen, C,.6 alkyl, C,-3 alkanoyl or
C|.6 alkoxycarbonyl; and R5 is an acidic functional group; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof.
It will be understood that Y or Y' preferably excludes those linker groups which are unstable in acid conditions such as those found in the stomach of a human or animal body, for example
With reference to the compounds of formula (I), the 5 to 7 heterocyclic can be an, optionally substituted, saturated or unsaturated ring with up to three heteroatoms independently selected from nitrogen, oxygen and sulphur. An example of such a ring is an oxazolidinone, oxazolone and thiazolone.
Linker group Y or Y'can comprise a monocyclic ring or a bicyclic ring. With reference to the compounds of formula (I), 'monocyclic ring' means a 5 to 7 membered ring. It can be an, optionally substituted, preferably aromatic ring with up to three heteroatoms independently selected from nitrogen, oxygen and sulphur. Examples of such rings include phenyl, pyrimidinyl, pyridyl, imidazolyl, thienyl, thiazolyl, pyridazinyl and pyrrolyl. Other examples include morpholino, tetrahydropyridyl or tetrahydropyrazolyl.
With reference to the compounds of formula (I), 'bicyclic ring system' means an 8 to 10 membered fused ring system wherein one or both rings may contain ring heteroatoms. The ring system may be totally or partially saturated, optionally substituted and contain up to five heteroatoms independently selected from oxygen, nitrogen or sulphur. Examples of suitable ring systems include naphthalene, quinazoline, benzothiophene, benzoxazole, benzothiazole, and benzofuran and the corresponding hydro derivatives, e.g. tetrahydronaphthalene and dihydroquinazoline .
The term 'acidic functional group' means a group which incorporates an acidic hydrogen and includes carboxylic acids, tetrazoles, acyl sulphonamides, sulphonic and sulphinic acids.
In one aspect of the invention, the group Y' or Y is the group
- D - (E)p - (F)q - G - where D, E, F, G, p and q are as defined below. Thus suitable compounds of the invention are compounds of formula (II)
wherein
A, B, R1 to R5, m and n are as hereinbefore defined;
D and G are each independently C,_4 alkyl or C2.4 alkenyl and each carbon is optionally substituted with halogeno, hydroxy, amino, nitro, phenyl, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl, C,.6alkanoyl, C2.6alkynyl, C,.5alkoxy,
C2.6alkenyloxy, C2.6alkynyloxy, C,.6 alkylamino, di-[(C,.6)alkyl]amino, C2.6alkanoylamino
N-C,.6alkylcarbamoyl, C,.6alkoxylcarbonyl, J^,N-di-[(C1.6alkyl]carbamoyl, C alkoxylC,.
6alkyl, (CH2),.OH where r is 1 or 2, -CO2R7 and CONR7R8 where R7 and R8 are independently hydrogen or C,.6 alkyl, or D and A can be taken together to form a 5 to 7 membered ring, optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl,
C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C|.6 alkyl]amino and C2.6alkanoylamino;
E is phenyl or a monocyclic heterocycle both optionally substituted with up to 3 substituents selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy,
C2.6alkynyloxy, C,.6alkylamino, di-[C,.6alkyl] amino, C2.6alkanoylamino, C3.6 alkenoyl- amino,
C3.6alkynoylamino, C,.6alkoxycarbonyl, N-C,.6alkylcarbamoyl, N,N-di-[C,.6 alkyl]carbamoyl,
C,.6alkanoyl, C,.4alkoxylC,.6alkyl, (CH2)sOH where s is 1 or 2, -CO2R9 and CONR9R10 where
R9 and R10 are independently hydrogen or C,.6 alkyl or E and D can be taken together to form a bicyclic ring system, optionally substituted with up to 3 substituents selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2.6alkenyl, C2_
6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, CLgalkylamino, di-[C,.6 alkyl]amino and
C2.6alkanoylamino;
F is selected from oxygen, sulphur, amino or CRnR12; p and q are each independently 0 or 1 ; R" and R12 are each independently selected from hydrogen, halogeno, hydroxy, amino, nitro, phenyl, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl, C,.6alkanoyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,_6 alkylamino, di-[(C,.6)alkyl]amino, C,.6alkanoylamino, N-C,.6alkylcarbamoyl, C,.6alkoxylcarbonyl, N,N-di-[(C,.6alkyl]carbamoyl, C,.4alkoxylC,.6alkyl, (CH2)uOH where u is 1 or 2, -CO2R15 and CNNR,5R16 where R15 and R16 are independently hydrogen or C,.6 alkyl with the proviso that not more than one ring system can be formed from taking together two groups from R4, A, D and E; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof.
With reference to the compounds of formula (II), the 5 to 7 membered ring that can be formed by taking together A and D is a heterocycle ring. It can be an, optionally substituted, saturated or unsaturated ring with up to three heteroatoms independently selected from nitrogen, oxygen and sulphur. An example of such a ring is an oxazolidinone, oxazolone and thiazolone.
With reference to the compounds of formula (II), 'monocyclic heterocycle' means a 5 to 7 membered ring. It can be an, optionally substituted, preferably aromatic ring with up to three heteroatoms independently selected from nitrogen, oxygen and sulphur. Examples of such rings include pyrimidinyl, pyridyl, imidazolyl, thienyl, thiazolyl, pyridazinyl and pyrrolyl.
In a further preferred embodiment, the "monocyclic heterocycle" is a non-aromatic heterocyclic ring. Preferably, the rings are linked either to the groups D and/or F by means of a nitrogen atom. Such groups include morpholino, tetrahydropyridyl or tetrahydropyrazolyl.
With reference to the compounds of formula (II), 'bicyclic ring system' means an 8 to 10 membered fused ring system wherein one or both rings may contain ring heteroatoms. The ring system may be totally or partially saturated, optionally substituted and contain up to five heteroatoms. independently selected from oxygen, nitrogen or sulphur. Examples of suitable ring systems include naphthalene, quinazoline, benzothiophene, benzoxazole, benzothiazole, and benzofuran and the corresponding hydro derivatives, e.g. tetrahydronaphthalene and dihydroquinazoline.
The term 'acidic functional group' means a group which incorporates an acidic hydrogen and includes carboxylic acids, tetrazoles, acyl sulphonamides, sulphonic and sulphinic acids. Particularly preferred values for E in formula (II) is phenyl. Groups D and F are preferably arranged in the ortho- or meta- positions on phenyl ring E, and most preferably are orientated meta- to each other.
Alternatively, E is a monocyclic heterocycle as defined above, and in particular is an N-linked 6 membered non-aromatic heterocycle.
Preferably A' in formula (I) is NH or NR6 where R6 is C,.6alkyl such as methyl or C2_ 6alkenyl such as ethen-2-yl. More preferably A' (or A in Formula (IA) and (II)) is NH or NCH3 and most preferably A or A' is NH.
Preferably, R1 is a C,.6alkyl group such as methyl, which is in the ortho position on the phenyl ring relative to the ureido group. Preferably m is 1.
Preferably R2 and R3 are hydrogen or C,_4 alkyl and most preferably are both hydrogen.
A particular preferred value for B is oxygen.
Particular values for R4 include C^alkyl such as methyl, or C,_6 alkoxy such as methoxy. In this case, n is suitably 0, 1 or 2. A particularly preferred group of compounds of formula (I) are those of formula (III)
where R', R2, R3, A, B, Y, R5 and m are as defined above and R4a is either hydrogen or C,_ 6alkoxy such as methoxy, and R4b is either hydrogen or C,.6alkyl such as methyl.
A preferred value for F in formula (II) is oxygen.
Alternatively, q is 0.
Most preferably R5 is carboxy.
Suitable values for R1 to R\ R6, R1 ' to R16 and for various substituents on Y(or Y'), D, E, F, G or on any ring formed between Yor Y' and A or A', A or A' and D, D and E, A or A' and R4 include :- or halogeno: fluoro, chloro, bromo and iodo or C,.6alkyl: methyl, ethyl, propyl, isopropyl and tert-butyl; or C2.6alkenyl: vinyl, allyl and but-2-enyl; or C,.6alkanoyl formyl, acetyl, propionyl or butyryl; or C2.6alkynyl: ethynyl, 2-propynyl and but-2-ynyl; or C,.6alkoxy: methoxy, ethoxy, propoxy, isopropoxy and butoxy; or C2.6alkenyloxy: vinyloxy and allyloxy; or C2.6alkynyloxy: ethynyloxy and 2-propynyloxy; or C,.6alkylamino: methylamino, ethylamino, propylamino isopropylamino and butylamino; for di-C,.6alkylamino: dimethylamino, diethylamino; for C2.6alkanoylamino: acetamido, propionamido and butyramido; for N-C,.6alkylcarbamoyl: N-methylcarbamoyl, N-ethylcarbamoyl and N-propylcarbamoyl; for N,N-di-C alkylcarbamoyl: N,N-dimethylcarbamoyl,
N-ethyl-N-methylcarbamoyl and
N,N-diethylcarbamoyl; for C i .ήalkoxy carbony 1 : methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and tert-butoxycarbony 1 ; for C|_4alkoxyC alkyl: methoxymethyl, ethoxymethyl,
1 -methoxymethyl, 2 -methoxy ethyl, Particularly suitable compounds of formula (II) or pharmaceutically acceptable salts thereof include are those wherein, unless otherwise stated each of R1 to R16, A, B, D to G, m, p to u has any of the meanings defined hereinbefore or below in sections a to h a) B is oxygen, D and G are each independently a C alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen and R5 is carboxy. b) B is oxygen, D and G are each independently a C alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen and is in the meta position with respect to E and R5 is carboxy. c) B is oxygen, D and G are each independently a C alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen, R5 is carboxy and R1 and R4 are each independently C,.6 alkyl or C,.6 alkoxy. d) B is oxygen, D and G are each independently a CM alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen, R5 is carboxy, R1 and R4 are each independently C,.6 alkyl or C,.6 alkoxy and m and n are both 0 orl. e) B is oxygen, D and G are each independently a C,.4 alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen, R5 is carboxy and R2 and R3 are each independently C 6 alkyl, preferably methyl. f) B is oxygen, D and G are each independently a CM alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen, R5 is carboxy and R6 is C,_6 alkyl, preferably methyl g) B is oxygen, D is a CM alkyl, optionally substituted as hereinbefore defined, E is phenyl, q is zero and G is a C alkyl or C alkenyl, optionally substituted as hereinbefore defined and R3 is carboxy. h) B is oxygen, D and G are each independently C,_4 alkyl, optionally substituted as hereinbefore defined, E is phenyl, F is oxygen, A and one of R4 together form a five membered ring and R5 is carboxy.
Other particular groups are compounds where i) B is oxygen, D and G are each independently a C,.4 alkyl, optionally substituted as hereinbefore defined, q is 0, E is morpholino which is N-linked to the group G and is linked to D at the 2 position on the morpholine ring, and R5 is carboxy. j) B is oxygen, D and G are each independently a CM alkyl, optionally substituted as hereinbefore defined, q is 0, E is tetrahydropyridyl which is N-linked to the group G and is linked to D at the 4 position on the ring, and R5 is carboxy; k) B is oxygen, D and G are each independently a C,_4 alkyl, optionally substituted as hereinbefore defined, q is 0, E is tetrahydropyridyl which is N-linked to the group D and is linked to G at the 4 position on the ring, and R5 is carboxy;
1) B is oxygen, D and G are each independently a C alkyl, optionally substituted as hereinbefore defined, q is 0, E is tetrahydropyridyl which is N-linked to the group G and is linked to D at the 2 position on the ring, and R5 is carboxy; m) B is oxygen, D and G are each independently a C,_4 alkyl, optionally substituted as hereinbefore defined, q is 0, E is tetrahydropyrazinyl which is N-linked to the group D and G, and R5 is carboxy.
Pharmaceutically acceptable salts include acid addition salts such as salts formed with mineral acids, for example, hydrogen halides such as hydrogen chloride and hydrogen bromide, sulphonic and phosphonic acids; and salts formed with organic acids, especially citric, maleic, acetic, oxalic, tartaric, mandelic, p-toluenesulphonic, methanesulphonic acids and the like. In another aspect, suitable salts are base salts such as alkali metals salts, for example, sodium and potassium; alkaline earth metal salts such as magnesium and calcium; aluminium and ammonium salts; and salts with organic bases such as ethanolamine, methylamine, diethylamine, isopropylamine, trimethylamine and the like. Such salts may be prepared by any suitable method known in the art.
In vivo hydrolysable derivatives include, in particular, pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent compound. Such esters can be identified by administering, for example, intravenously to the test animal, the compound under test and subsequently examining the test animal's body fluids. Suitable in vivo hydrolysable esters for hydroxy include acetyl and for carboxy include, for example, alkyl esters, dialkylaminoalkoxy esters and C,.6alkoxy methyl esters for example methoxymethyl, C -alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C3.8 cycloalkoxycarbonyloxyC,.6alkyl esters for example 1 -cyclohexylcarbonyloxy ethyl; l,3-dioxolan-2-ylmethyl esters for example 5-methyl-l,3-dioxolan-2-ylmethyl; and C,.6alkoxycarbonyloxy ethyl esters for example 1-methoxycarbonyloxyethyl.
It is to be understood that insofar as certain of the compounds of formula (I) as hereinbefore defined may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses the property of inhibiting the interaction between VCAM-1 and fibronectin with integrin α4β,. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art. These include, for example, synthesis from optically active starting materials or by resolution of a racemic form.
Particular Examples of compound of formula (I) are given in Tables 1, 2 and 3.
Table 2
Table 3
The activities of the compounds of this invention to inliibit the interaction between
VCAM-1 and fibronectin with integrin α4βi may be determined using a number of in vitro and in vivo screens, as hereinafter defined. For example, compounds of formula (I) preferably have an IC50 of <10μM, more preferably <lμM in the MOLT-4 cell/Fibronectin assay hereinafter described.
In order for it to be used, a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof is typically formulated as a pharmaceutical composition in accordance with standard pharmaceutical practice.
Thus, according to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof and a pharmaceutically acceptable carrier. The pharmaceutical compositions of this invention may be in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for nasal use, for example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example as a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oily solution or suspension, or a depot formulation with drug incorporated in a biodegradable polymer. The composition may be in a form suitable for topical administration such as for example creams, ointments and gels. Skin patches are also contemplated. For these purposes, the compositions of this invention may be formulated by means known in the art, such as for example, as described in general terms, in Chapter 25.2 of Comprehensive Medicinal Chemistry, Volume 5, Editor Hansch et al, Pergamon Press 1990. Furthermore, the pharmaceutical composition of the present invention may contain one or more additional pharmacological agents suitable for treating one or more disease conditions referred to hereinabove in addition to the compounds of the present invention. In a further aspect, the additional pharmacological agent or agents may be co-administered, either simultaneously or sequentially, with the pharmaceutical compositions of the invention.
The composition of the invention will normally be administered to humans such that the daily dose will be 0.01 to 75mg/kg body weight and preferably 0.1 to 15mg/kg body weight. A preferred composition of the invention is one suitable for oral administration in unit dosage form for example a tablet or capsule which contains from 1 to 1 OOOmg and preferably 10 to 500mg of a compound according to the present invention in each unit dose. Thus, according to yet another aspect of the invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof for use in a method of therapeutic treatment of the human or animal body.
In yet a further aspect of the invention the present invention provides a method of treating a disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor α4β, in need of such treatment which comprises administering to said warm-blooded mammals an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof.
The present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof in the production of a medicament for use in the treatment of a disease or medical condition mediated by the interaction between fibronectin and/or VCAM-1 (especially VCAM-1) and the integrin receptor α4β,
In a preferred embodiment the mammal in need of treatment is suffering from multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease, psoriasis, atherosclerosis, transplant rejection, inflammatory bowel disease, insulin-dependent diabetes and glomerulonephritis.
Preferred compounds of formula (I) for use in these various embodiments of the invention are as set out above and include compounds of formula (IA) or (II). In another aspect of the invention, there is provided a process for preparing a compound of formula (I), a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof which method comprises either (a) reacting a compound of formula (IV)
where A\ R1, R2, R\ R4, m and n are as defined in relation to formula (I), with a compound of formula (V) where B and Y' are as defined in relation to formula (I), Z is a leaving group, such as halo, and R'7 is a group R3 as defined in relation to formula (I) or a protected form thereof: or
(b) reacting a compound of formula (VI)
where A\ B, Y' R3, R4 and n are as defined in relation to formula (I) and R17 is as defined in relation to formula (V) with a compound of formula (VII)
where R' and m are as defined in relation to formula (I); and thereafter if desired or necessary, i) removing any protecting groups; and ii) optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable derivative.
Particular protected groups R17 are ester groups an in particular C,.6alkyl esters. Starting materials for the process may be obtained by standard organic chemistry procedures. The preparation of such starting materials is described in the following representative processes in conjunction with the accompanying Examples. Alternative starting materials are obtaintable by procedures which are analogous to those desctibed below and within the ordinary skill of an organic chemist. One process (a) above, comprises coupling together a compound of formula (IV) and (V) above, via the formation of a urethane or a carbamosulfanyl. The compounds are suitably reacted together in the presence of an inert solvent and in basic conditions.
A suitable solvent system for the aforementioned process is dichloromethane or tetrahydrofuran (THF) in the presence of pyridine.
A particular compound of formula (V) is a compound of formula (VIII)
where Y is the group - D - (E)p - (F)q - G - and where B, D, E, F, G, p and q are as hereinbefore defined and R17 is a COOC,.6 alkyl. A particular example of a compound of formula (IV) is a compound of formula (IX)
where R1, R2, R3, R4, n and m are as defined in relation to formula (I).
An example of a compound of formula (VIII) where B is oxygen, D is CH2 ,E is phenyl, p is 1, q is 1, F is oxygen, G is C3 alkyl and R17 is COOMe
Compounds of formula (V) can be prepared by reacting a compound of formula (X)
with phosgene in the presence of toluene/dichloromethane. Where B is oxygen, this compound is the corresponding alcohol. These alcohols can be prepared by reaching 3-hydroxybenzyl alcohol and methyl 4- bromobutyrate under basic conditions. It will be appreciated that different alcohols can be prepared by substituting, for example, methyl 4-bromobutyrate by t-butylbromoacetate.
An example of a compound of formula (IX) where m and n are both 1, R1 is methyl, R2 and R3 are both hydrogen and R4 is methoxy is
Such a compound can be prepared from the corresponding 3-methoxy-4(N'-(2- methylphenyl)urea)nitrobenzene. The latter can be prepared from the reaction of the corresponding methoxy-nitroaniline together with methylphenylisocyanate.
It will appreciated by the skilled person that in some of the reactions it may be necessary to protect sensitive groups in the molecule. Protecting groups may typically be chosen from any of the groups described in literature or known to the skilled person.
Suitable protecting groups for an amino group include for example, formyl, and alkoxycarbonyl groups, for example tert-butoxycarbonyl.
Suitable protecting groups for a hydroxy group include lower alkyl groups, for example tert-butyl, and acyl groups, for example an alkanoyl group such as acetyl.
Suitable protecting groups for a carboxy group include, an esterifying group, for example a methyl or ethyl group. These groups may be removed by any convenient method described in the literature or known to the skilled person for removal of the specific protection group in question. The method of removal is chosen so as to minimise disturbance on the other groups in the molecule. For example when the protecting group is an acyl group or a C,_2 alkyl group it may be removed by hydrolysis with a suitable base such as, for example, sodium hydroxide. A tert-butyl protecting group may be removed with, for example, an organic acid such as trifluoroacetic acid .
An alternative method of preparing a compound of formula (I), a pharmaceutically acceptable salt or an in vivo hydrolysable derivative comprises reacting together a compound of formula (VI) and (VII), to form a urea linkage. The reaction is suitably effected in the presence of an inert solvent. Suitable inerts solvents for the aforementioned process include dichloromethane, THF or ethyl acetate. As before, any functional group is protected if necessary and i) removing any protecting groups; and ii) optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable derivative.
A particular example of a compound of formula (VI) is a compound of formula (XI)
where Y is the group - D - (E)p - (F)q - G - where R4, R'7' B, D, E, F, G, n, p and q are as hereinbefore defined. A particular example of a compound of formula (VII) is a compound of formula (XII)
where R' and m are as hereinbefore defined. An example of a compound of formula (V) is
(XIII) Such a compound can be prepared by reducing the corresponding nitroaniline derivatives. Thus compounds of formula (VI) can be prepared by reduction of a compound of fomula (XVI)
where A', Y', B, R17, R4 and n are as defined above.
A suitable reduction regime would be iron powder in the presence of ammonium chloride/water/methanol .
The nitroaniline derivative of formula (XVI) where A' is NH, can be prepared by reacting an appropriate compound of formula (XIV)
where B, Y' and R17 are as defined above, and B in particular is oxygen, with an isocyanate of formula (XV)
The reaction is suitably effected in an organic solvent such as dichloromethane of tetrahydrofuran (THF) in the present of a base such as triethylamine. Thus an exemplary scheme is as follows :
Inert solvent e.g dichloromethane or THF + small amt. base e,g triethylamine
The invention is further limited by the following biological test methods, data and non-limiting examples. Example 1 - Preparation of 4-(3-([({4-[(2-toIuidinocarbonyι)amino]anilino} carbonyl)oxy]methvUphenoxy)butanoic acid (Compound No. 1 in Table 1)
To methy l-4-(3 - { [( { 4- [(2-toluidinocarbonyl)amino]anilino } carbonyl)oxy]methyl } phenoxy)butanoate (0.085g) in dimethyl sulphoxide (DMSO) (1ml) was added 2N aqueous sodium hydroxide (0.2ml). The mixture was stirred for lhr at ambient temperature and then water (5ml) added. The pH was adjusted to pH 2 with concentrated hydrochloric acid. The precipitated solid product was filtered and washed with water and then dried to give the acid (0.055g) as a dark brown solid. (68%) Mass spectrum M-H 476.8
1H nmr (DMSO-d6) : 1.9 (m) 2H; 2.2 (s), 3H; 2.4 (t), 2H; 4.0 (t), 2H; 5.1 (s) 2H; 6.9 (m), 4H: 7.1 (m), 2H; 7.3 (t), 1H; 7.4 (s), 4H; 7.8 (m), 2H; 8.9 (s), 1H; 9.6 (s), 1H. a) Preparation of methyl 4-(3-hydroxymethyl)phenoxybutyrate
To a mixture of potassium carbonate (5.6g), 3-hydroxybenzyl alcohol (2.5g) in N- methylpyrollidinone (5ml) and methyl 4-bromobutyrate (2.2ml) were added followed by potassium iodide (2g). The mixture was stirred at room temperature for 48 hrs., added to water (30ml) and then extracted with diethyl ether (100ml). The organic layer was washed with dilute sodium hydroxide solution and brine. It was then dried over magnesium sulphate and evaporated to dryness. The residue was then purified by chromatography on silica using an increasingly polar mixture of ethyl acetate/ hexane (20% changing to 90%) to give methyl 4-(3-hydroxymethyl)phenoxybutyrate. (3.1g). 1H nmr (CDC1,) included the following resonances :
2.1 (m), 2H: 2.5 (t), 2H; 3.7 (s), 3H; 4.0 (t), 2H; 4.6 (s), 2H; 6.8 (q), 1H; 6.9 (m), 2H; 7.2 (m), 1H. b) Preparation of methyl-4-(3-{[({4-[(2-toluidinocarbonyl)amino] anilino}carbonyl)oxy]methyl}phenoxy)butanoate
To methyl 4-(3-hydroxymethyl)phenoxybutyrate (0.22g) in dichloromethane (3ml) was added 20% phosgene in toluene (3ml) and the mixture allowed to stand for 18hrs, evaporated and part of the residue (0.15g) in dichloromethane (2ml) added to 4-(2- tolylureido)aniline (CAS Registry Number 202874-38-2 and as described in WO 98/04247) (0.12g) in dichloromethane (3ml) containing pyridine (O.lg). The mixture was stirred for 2hrs and then evaporated and the residue purified by chromatography on silica using an increasingly polar mixture of methanol/ chloroform (0% changing to 10%) to give, after evaporation and trituration in diethyl ether the above material (0.15g) Mass spectrum: M+H 492 1H nmr (DMSO-d6) included the following resonances :
2.0 (m), 2H; 2.2 (s), 3H; 2.5 (m), 2H; 3.6 (s), 3H; 4.0 (t), 2H; 5.1 (s), 2H; 6.9 (m), 4H;
7.1 (m), 2H; 7.3 (t), 1H; 7.4 (s), 4H; 7.8 (m), 2H; 8.9 (s), 1H; 9.6 (s), 1H.
Example 2 - Preparation of 4-(3- ({methyl-4-[(2-toluidinocarbonvDaminolanilino] carbonyl)oxylmethy phenoxy")butanoic acid (Compound No 5 in Table 1)
This was prepared by hydrolysis of methyl-4-(3-{[({methyl-4-[(2- toluidinocarbonyl)amino]anilino} carbonyl)oxy]methyl}phenoxy)butanoate using the process described in example 1
Mass spectrum M+H 492
1H nmr (DMSO-d6) included the following resonances :
1.9 (m), 2H; 2.2 (s), 3H; 2.4 (t), 2H; 3.2 (s), 3H; 4.0 (t), 2H; 5.1 (s), 2H; 6.8 (m), 3H; 6.9 (t), 1H; 7.2 (m), 6H; 7.4 (d), 2H; 7.8 (d), 2H; 7.9 (s), 1H; 9.0 (s), 1H. a) Preparation of methyl 4-[3-({[(4-nitroanilino)carbonyl]oxy} methyI)phenoxy]butanoate
To methyl 4-(3-hydroxymethyl)phenoxybutyrate (2.24g) in dichloromethane (10ml) was added 4-nitrophenylisocyanate (2g) and triethylamine (3 drops). The mixture was stirred for 2 hrs., evaporated to dryness and the residue triturated with diethyl ether to give methyl 4-[3-({[(4-nitroanilino)carbonyl]oxy}methyl)phenoxy]butanoate as a yellow powder (3.5g) 1H nmr (CDC13) included the following resonances :
2.1 (m), 2H; 2.5 (t), 2H; 3.7 (s), 3H; 4.0 (t), 2H; 5.2 (s), 2H; 6.9 (m), 3H; 7.1 (s), 1H; 7.3 (d), lH; 7.6 (d), 2H; 8.2 (d), 2H. b) Preparation of methyl 4-[3-({[(methyl-4-nitroanilino)carbonyl]oxy} methyl)phenoxy]butanoate
To methyl 4-[3-({[(4-nitroanilino)carbonyl]oxy}methyl)phenoxy]butanoate(lg) in N- methylpyrollidinone (5ml) added sodium hydride (1.1 equ.) and methyl iodide (1.3 equ.) and the mixture stirred for 4hrs, added to water (20ml) and extracted with diethyl ether (50ml), this washed with brine, dried and evaporated to dryness. The residue was purified by chromatography on silica using an increasingly polar mixture of ethyl acetate/ hexane (10% changing to 30%) to give product as a gum (0.8)g which crystallised on standing.
1H nmr (CDC1,) included the following resonances :
2.1 (m), 2H; 2.5 (t), 2H; 3.4 (s), 3H; 3.7 (s), 3H; 4.0 (t), 2H; 5.2 (s), 2H; 6.9 (m), 3H; 7.3 (m), lH; 7.6 (d), 2H; 8.2 (d), 2H. c) Preparation of methyI-4-(3-{[({methyl-4-[(2-toluidinocarbonyl)amino] ani!ino}carbonyl)oxy]methyl}phenoxy)butanoate
To methyl 4-[3-({ [(methyl-4-nitroanilino)carbonyl]oxy}methyl)phenoxy] butanoate(0.7g) in methanol (10ml) was added iron powder (0.7g) and a solution of ammonium chloride (0.13g) in water (4ml). The mixture was refluxed for lhr., ethyl acetate (30ml) added and the mixture filtered to remove metal salts, and evaporated to dryness. The residue in dichloromethane was dried with magnesium sulphate, filtered and evaporated to dryness. The residue in dichloromethane (5ml) was treated with o-tolylisocyanate (1.1 equ.) and allowed to stand for 18hrs., evaporated to dryness and triturated with diethyl ether to give methyl-4-(3-{[({methyl-4-[(2-toluidinocarbonyl)amino] anilino} carbonyl)oxy]methyl}phenoxy]butanoate (0.6g) as an off-white solid.
1 H nmr (DMSO-d6) included the following resonances :
2.0 (m), 2H; 2.2 (s), 3H; 2.45 (m), 2H; 3.2 (s), 3H; 3.6 (s), 3H; 3.9 (t), 2H; 5.0 (s), 2H; 6.8
(m), 3H; 6.9 (m), 1H; 7.2 (m), 5H; 7.4 (d), 2H; 7.8 (d), 1H; 7.9 (s), 1H; 9.0 (s), 1H. „„
- 29 -
Example 3 - Preparation of 4-(3-{[({4-[(2-toluidinocarbonvDamino]anilino) carbonvDoxy] methyl} phenoxy)ethanoic acid (Compound No. 6 in Table 1)
Tertiary-butyl-4-(3 - { [( { 4- [(2-toluidinocarbonyl)amino]anilino } carbonyl) oxy]methyl}phenoxy)ethanoate (0.6g) was stirred in a mixture of dichloromethane (4ml) and trifluoroacetic acid (4ml) for 2hrs. and then evaporated to dryness. The residue was triturated in diethyl ether to give 4-(3-{[({4-[(2- toluidinocarbonyl)amino]anilino}carbonyl)oxy]methyl}phenoxy)ethanoic acid as a white powder (0.48g, 87% ) Mass spectrum M-H 448
1H nmr (DMSO-d6) included the following resonances :
2.2 (s), 3H; 4.6 (s), 2H; 5.1 (s), 2H; 6.9 (m), 4H; 7.1 (m), 2H; 7.3 (t), 1H; 7.35 (s), 4H; 7.8
(m), 2H; 8.9 (s), 1H; 9.6 (s), 1H. a) Preparation of t-butyl 4-(3-hydroxymethyl)phenoxyacetate To 3-hydroxybenzyl alcohol (95 g) in acetone (10ml) was added potassium carbonate
(1 lg ) and 1 spoonful of potassium iodide and the mixture stirred whilst t-butylbromo acetate (6.5ml) was added. The mixture was then stirred for a further 18 hrs. The acetone was then evaporated and the residue partitioned between water (60ml) and ethyl acetate (60ml). The organic layer was dried and evaporated and the residue purified by chromatography on silica using an increasingly polar mixture of ethyl acetate in hexane. The appropriate fractions evaporated to dryness gave 7g of white crystalline product. 1 H nmr (CDC13) contained the following resonances : 1.5 (s), 9H; 4.5 (s), 2H; 4.65 (d), 2H; 6.8 (q), 1H; 7.0 (m), 2H; 7.3 (t), 1H. b) Preparation of t-butyl-4-[3-({[(4-nitroanilino)carbonyl]oxy} methyl)phenoxy]ethanoate
To t-butyl 4-(3-hydroxymethyl)phenoxyacetate (1.2g) in dichloromethane (10ml) was added 4-nitrophenylisocyanate (1.1 equ.) and triethylamine (3 drops). The mixture was stirred for 2 hrs., evaporated to dryness and the residue triturated with diethyl ether to give t-butyl-4- [3-({[(4-nitroanilino)carbonyl]oxy}methyl)phenoxy]ethanoate as a yellow powder (1.7g) lH nmr (DMSO-d6) included the following resonances :
1.4 (s), 9H; 4.6 (s), 2H; 5.15 (s), 2H; 6.85 (q), 1H; 6.95 (s), 1H; 7.0 (d), 1H; 7.3 (t), 1H; 7.7 (d), 2H; 8.2 (d), 2H. c) Preparation of t-butyl-4-(3-{[{(4-[(2-toluidinocarbonyl)amino] anilino}carbonyl)oxy]phenoxy)ethanoate
T-buty 1-4- [3 -( { [(4-nitroanilino)carbony 1] oxy } methy l)phenoxy] ethanoate(0.7g) was reduced and reacted with o-tolylisocyanate by the method described in example 2 to give t- butyl-4-(3-{[({4-[(2-toluidinocarbonyl)amino]anilino}carbonyl)oxy]methyl} phenoxy)ethanoate (0.8g) as an off-white powder. IH nmr (DMSO-d6) included the following resonances :
1.4 (s), 9H; 2.2 (s), 3H; 4.6 (s), 2H; 5.1 (s), 2H; 6.9 (m), 4H; 7.1 (m), 2H; 7.3 (t), IH; 7.4 (s), 4H; 7.8 (m), 2H; 8.85 (s), IH; 9.6 (s), IH.
Example 4 - Preparation of 4-(3-{K(3-methoxy-4-[(2-toluidinocarbonyl)amino] anilino}carbonyl)oxy]methyl)phenoxy)butanoic acid (Compound No. 2 in Table 1)
Methyl 4-(3 - { [( { 3 -methoxy -4- [(2-toluidinocarbonyl)amino]anilino } carbonyl) oxy]methyl}phenoxy)butanoate(0.15 g) was hydrolysed by the method described in example 1 to give 0.07g of product as a dark powder. Mass spectrum M+H 508
IH nmr (DMSO-d6) included the following resonances:
1.9 (m), 2H; 2.2 (s), 3H; 2.4 (t), 2H; 3.8 (s), 3H; 4.0 (t), 2H; 5.1 (s), 2H; 6.9 (m), 5H; 7.1 (m), 2H; 7.3 (m), 2H; 7.8 (d), IH; 8.0 (d), IH; 8.4 (s), IH; 8.5 (s), IH; 9.6 (s), IH. a) Preparation of 3-methoxy-4(N'-(2-methylphenyl)urea) nitrobenzene
2-methoxy-4-nitroaniline(16.8g) in ethyl acetate(90ml) was treated with stirring with 2-methylphenylisocyanate (16.1ml). The solution was heated to 60°C for 12 hours. The solution was then chilled to 0°C and the precipitate filtered and washed with cold ethyl acetate. This gave 3-methoxy-4(N'-(2-methylphenyl)urea)nitrobenzene (lOg). lH nmr (DMSO-d6) included the following resonances:
2.2 (s), 3H; 4.0 (s) 3H; 6.9 (t) IH; 7.2 (m) 2H; 7.7 (d) IH; 7.8 (s) IH; 7.9 (d) IH; 8.4 (d) IH; 8.8 (s) IH; 9.2 (s) IH. m/Z 302(M+H), 300(m-H). b) Preparation of N-(4-amino-2-methoxyphenyl)-N'-(2-methylphenyl)urea) At ambient temperature a rapidly stirred solution of 3-methoxy-4(N'-(2- methylphenyl)urea)nitrobenzene(5g) in DMF (50ml) containing 10% palladium on carbon (500mg) was exposed to an atmosphere of hydrogen. When uptake of hydrogen had ceased the solution was filtered and the filter cake washed with dichloromethane. The combined filtrates were evaporated to dryness under reduced pressure, triturated with diethylether and filtered to give product (4.14g) as a off- white solid. IH nmr (DMSO-d6) included the following resonances:
2.2 (s) 3H; 3.8 (s) 3H; 4.8 (s) 2H; 6.1 (d) IH; 6.3 (s) IH; 6.8 (t) IH; 7.1 (m) 2H; 7.5 (d) IH; 7.8 (d) IH; 8.05 (s) IH; 8.15 (s) IH. m/Z 272(M+H) c) Preparation of methyl 4-(3-{[({3-methoxy-4-[(2-toluidinocarbonyl)amino] anilino}carbonyl)oxy] methyl} phenoxy)butanoate
N-(4-amino-2-methoxyphenyl)-N'-(2-methylphenyl)urea)(0.27g) was treated with the chloroformate of methyl 4-(3-hydroxymethyl)phenoxybutyrate as described in example 1 to give product (0.16g).
IH nmr (DMSO-d6) included the following resonances : 2.0 (m), 2H; 2.2 (s), 3H; 2.5 (m), 2H; 3.6 (s), 3H; 3.8 (s), 3H; 4.0 (t), 2H; 5.1 (s), 2H;
6.9 (m), 5H; 7.1 (m), 2H; 7.3 (m), 2H; 7.8 (d), IH; 8.0 (d), IH; 8.4 (s), IH; 8.5 (s), IH; 9.6 (s), IH.
Example 5 - Preparation of 2-(3-{2[((4[2-toIuidinocarbonyl)amino]anilino} carbonyl)oxylethyl}phenoxy)acetic acid (Compound No. 7 in Table 1)
Tertiary -butyl-2-(3 - { 2 [( { 4 [2-toluidinocarbonyl)amino]anilino } carbonyl)oxy] ethyl } phenoxy)ethanoate (0.5g) was hydrolysed by the method described in example 3 (0.41 g) Mass spectrum M-H 462 IH nmr (DMSO-d6) included the following resonances :
2.2 (s), 3H; 2.9 (t), 2H; 4.3 (t), 2H; 4.7 (s), 2H; 6.7 (q), IH; 6.9 (m), 3H; 7.1 (m), 3H; 7.3 (s), 4H; 7.8 (m), 2H; 8.8 (s), IH; 9.5 (s), IH. a) Preparation of t-butyl 3-(2-hydroxyethyl)phenoxyacetate
To 3-(2-hydroxyethyl)phenol (2.8g) in N-methylpyrollidinone (8ml) was added potassium carbonate (5.6g) and t-butylbromoacetate (4.4g). The mixture was stirred for 18hrs, added to water (40ml) and extracted into diethyl ether. The organic layer was washed with brine, dried and evaporated to dryness to give t-butyl 3-(2-hydroxyethyl)phenoxyacetate (5.3g) used without further purification
1 H nmr (CDC13) included the following resonances :
1.5 (s), 9H; 2.8 (t), 2H; 3.8 (q), 2H; 4.5 (s), 2H; 6.8 (m), 3H; 7.2 (t), IH. b) Preparation of t-butyl 2-[3-(2-{[(4-nitroanilino)carbonyl]oxy} ethyl)phenoxy] ethanoate
Tertiary-butyl 3-(2-hydroxyethyl)phenoxyacetate (2.5g) was reacted with 4- nitrophenylisocyanate (1.6g) by the method described in example 3 to give the product(2.9g) IH nmr (CDC1,) included the following resonances : 1.5 (s), 9H; 3.0 (t), 2H; 4.4 (t), 2H; 4.6 (s), 2H; 6.8 (m), 3H; 7.2 (m), 2H; 7.6 (d), 2H;
8.2 (d), 2H. c) Preparation of t-butyl-2-(3-{2[({4[2-toluidinocarbonyl)amino]anilino} carbonyl)oxy]ethyl}phenoxy)ethanoate t-butyl 2-[3-(2-{[(4-nitroanilino)carbonyl]oxy}ethyl)phenoxy]ethanoate (0.8g) was reduced and reacted with o-tolylisocyanate by the method described in example 2 to give the product(0.7g) as a white powder.
1 H nmr (DMSO-d6) included the following resonances :
1.4 (s), 9H; 2.2 (s), 3H; 2.9 (t), 2H; 4.4 (t), 2H; 4.6 (s), 2H; 6.9 (m), 4H; 7.1 (m), 3H; 7.8 (m), 2H; 8.8 (s), IH; 9.5 (s), IH.
Example 6
Preparation of Compound No. 31 in Table 2
To the methyl ester of the Compound 31 (0.099g) in MeOH (1ml) was added 2N aq NaOH solution (0.08ml), and the mixture stirred at ambient temperature for 16 hrs. This was then evaporated to dryness, the residue dissolved in THF (5ml) and acidified with cone, hydrochloric acid. This solution was then adsorbed onto silica, and purified by chromatography on silica, using increasingly polar mixtures of CH2Cl2/MeOH (5%-20%) and the appropriate fractions evaporated to dryness to give the Compound 31 (0.054g) as an off- white solid (56%). MS M+H 515
NMR spectrum (in DMSO-d6) included the following resonances: 1.62(m) 2H, 1.80-2.04 (m) 2H, 2.05 (s) 3H, 2.20-2.30 (m) 7H, 2.62 (d) 2H, 2.68 (d) 2H, 3.82 (s) 3H, 4.04 (m) 3H, 6.95 (m) 2H, 7.14 (m) 2H, 7.76 (d) IH, 7.90 (s) IH, 8.52 (s) IH, 8.54 (s) IH, 8.80 (s) 1 a) Preparation of alcohol intermediate
2-(Hydroxymethyl) morpholine (0.8g) was dissolved in acetonitrile (15 ml), and to this solution were added anhydrous potassium carbonate (2.85g; 3 equivalents), potassium iodide (0.025g; catalytic amount) and methyl-4-bromobutyrate (0.95 ml; 1.05 equivalents). This reaction mixture was then stirred at 60° C for 16 hours. The cooled suspension was then filtered, washing with more acetonitrile, and the filtrate concentrated under reduced pressure to give the desired alcohol as a yellow oil (1.48g; 100% yield not purified).
MS Data: M+H 218 b) Preparation of nitrophenyl intermediate The alcohol intermediate of step 1 was reacted with 4-nitrophenylisocyanate as described in Example 2a to give the corresponding nitro intermediate of formula
MS M+H 426 NMR spectrum (in DMSO-d6) included the following resonances:
1.64-1.72 (m) 2H, 1.80-1.86 (m) IH, 1.92-2.04 (m) IH, 2.20 (s) 3H, 2.26-2.36 (m) 4H, 2.60- 2.64 (m) IH, 2.72-2.78 (m) IH, 3.42-3.52 (m) IH, 3.58 (s) 3H, 3.66 (m) IH, 3.80 (m) IH, 3.84 (s) 3H, 4.10 (d) 2H, 7.60 (s) IH, 7.78 (s) IH, 9.28 (s) IH c)Preparation of aniline intermediate
The nitro compound from (b) (0.47g) was dissolved in ethanol (10 ml) and ammonium formate (0.625g; 10 equivalents) was added. The reaction flask was flushed with argon, and the catalyst (10% Pd/C, 0.047mg; 0.1 equivalents by weight) was then added. The reaction was heated to reflux and stirred at this temperature for 1 hour. The reaction mixture was then cooled and filtered through a bed of celite, washing through with more ethanol. The solvent was removed under reduced pressure, and the residue dissolved in ethyl acetate (50ml). This solution was then washed with water, brine, dried over anhydrous magnesium sulphate and concentrated under reduced pressure to give the above aniline as a brown oil (0.43g; 98% yield).
MS Data: M+H 438 d) Preparation of Methyl Ester precursor to Compound 31 The aniline intermediate of step c was reacted with o-tolylisocyanate as described in Example 2c to yield the required methyl ester.
MS Data: M+H 529
Example 7 Preparation of Compound No. 29 in Table 2
To the methyl ester of the above (0.075g) in THF (2ml) was added a solution of LiOH.H20 (0.04g) in H20 (2ml), and the mixture stirred at ambient temperature for 16 hrs. This was acidified with cone, hydrochloric acid and evaporated to dryness. Purified by chromatography on silica, using increasingly polar mixtures of CH2Cl2/MeOH (5%-20%) and the appropriate fractions evaporated to dryness to give the above material (0.064g) as an off- white solid (88%).
MS M+H 455
Example 8
Using the methods of the Examples as described above, where Method A is as described in Example 1 , Method B is as described in Example 2, Method C is as described in Example 7, Method D is as described in Example 7, the following compounds whose structures are listed in Tables 1 , 2 and 3 were prepared:
Table 4
a) Alkyl (usually methyl or ethyl) ester intermediates (i.e. compounds of formula (I) where R5 is an methyl or ethyl carboxylic ester) used in the process were generally obtained as described in Example 2c. The characterising data where available of the esters are set out in Table 5.
Table 5
In the above Table, the compound nos refer to the acids which were ultimately derived from the methyl esters. Examples with the note 'alkylation' had the appropriate nitro intermediate alkylated as described in Example 2b. ai) The methyl ester of Compound 3 in Table 1 was obtained from a urea carbamate ester intermediate -ureidoaniline + chloroformate using a method analogous to that described in Example 1
MS M+H 462
NMR spectrum (in DMSO-d6) included the following resonances: 2.2 (s) 3H, 2.7 (t) 2H, 2.9 (t) 2H, 3.6 (s) 3H, 5.1 (s) 2H, 6.9 (m) IH, 7-7.4 (m) 8H, 7.8 (m) 2H, 8.8 (s) IH, 9.4 s) lH b) Details of the intermediate anilines of formula (VI) are set out in Table 6. In this Table, the method indicates the following: Y1 Fe/NH4Cl/EtOH/H2O As Ex 2c
Y2 HCO2NH4/Pd/C/EtOH As Ex 6c
Y3 H2/Pd/C/EtOH As Ex 4b
The compound No. refers to the Compound of formula (I) which was ultimately derived from the intermediate.
Table 6
c) The above described anilines were obtained from the corresponding nitro compounds of formula (XIV) as set out above using methods analogous to that of Example 2a. Data for the nitro compounds is set out in Table 7. Table 7
Again, the compound No. column refers to the compound of formula (I) ultimately obtained from this intermediate.
ci) In the case of the nitro compound used in the preparation of compound 54 in Table 3, (i.e. the compound of formula
a modified route was used.
To methyl 4-(3-hydroxymethyl)phenoxybutyrate (1.12g) in dichloromethane (6ml) was added 20%) phosgene in toluene (12ml) and the mixture allowed to stand for 18hrs, evaporated and the residue in dichloromethane (15ml) added to 4-nitroindoline (0.82g) in pyridine (2ml) and the mixture stirred overnight, evaporated to dryness and partitioned between aqueous acid and diethyl ether. A crystalline material precipitated and was filtered, washed with ether and dried to give the above (0.8g)
NMR
2. 0 (m) 2H, 2.4 (m) 2H, 3.2 (t) 2H, 3.6 (s) 3H, 4.0 (t) 2H, 4.1 9t) 2H, 5.2 (s) 2H, 6.9 (m) 3H,
7.3 (t) IH, 7.8 (m) IH, 8.1 (m) 2H Alcohol intermediates (of general formula (XIV) above) used in the preparation of the nitro compounds were prepared by various methods. These are outlined below or summarised in Table 8.
dl) Alcohol for use in the Preparation of Compound No. 28 in Table 1
Piperidine methanol (0.5g) was dissolved in dichloromethane (10 ml) and triethylamine (0.64 ml; 1.05 equivalents) was added, followed by methyl-4-bromobutyrate (0.6 ml; 1.05 equivalents). The resulting solution was stirred at room temperature for 16 hours, then diluted with a further 40 ml dichloromethane and washed with water (25 ml). The organic solution was dried using phase separating paper and concentrated under reduced pressure. Purification on a silica Bond Elut column using dichloromethane/methanol mixtures of increasing polarity as eluent gave the desired alcohol (Example 6 Id) as a yellow oil (0.309g; 33% yield).
MS Data: M+H 216
NMR Data: (CDC13) 1.20-1.34 (m) IH, 1.58-1.70 (m) 2H, 1.70-1.90 (m) 4H, 2.04 (m) IH, 2.14 (m) IH, 2.26 (m) IH, 2.36-2.44 (m) 4H, 2.66 (m) IH, 2.84 (m) IH, 3.56 (m) IH, 3.66 (m) lH, 3.68 (s) 3H,
d2) Alcohol for use in the Preparation of Compound No. 30 in Table 1
2-(Hydroxymethyl) morpholine (0.8g) was dissolved in acetonitrile (15 ml), and to this solution were added anhydrous potassium carbonate (2.85g; 3 equivalents), potassium iodide (0.025g; catalytic amount) and methyl-4-bromobutyrate (0.95 ml; 1.05 equivalents). This reaction mixture was then stirred at 60° C for 16 hours. The cooled suspension was then filtered, washing with more acetonitrile, and the filtrate concentrated under reduced pressure to give the desired alcohol (Example 63d) as a yellow oil (1.48g; 100%) yield not purified).
MS Data: M+H 218
d3) Alcohol for use in the Preparation of Compound No. 48 in Table 1
Method exactly in method d2, but using the alkyl chloride in place of the alkyl bromide. MS Data: (EI+) M+ 243
d4) Alcohol for use in the Preparation of Compound No. 4 in Table 1 To 3 -hydroxy acetophenone (7g) in NMP (70ml) was added potassium carbonate
(13.8g) and potassium iodide (2g), followed by methyl-4-bromobutyrate (6.2ml) and the mixture stirred for 18hrs, then added to water (200ml) and extracted with ethyl acetate. The organic extracts were wshed with brine and evaporated to dryness, purified by chromatography on silica (hexane/ethyl acetate) and the appropriate fractions evaporated to dryness. lg of this material was dissolved in ethanol and sodium borohydride (0.16g) was added and the mixture stirred for 18hrs, evaporated , and partitioned between dilute acid and diethyl ether. The organic layer was separated, dried and evaporated and the residue purified by chromatography on silica (10% ethyl acetate in hexane increasing to 90%). The aapropriate fractions evaporated to dryness gave an approx. 50:50 mixture of ethyl & methyl 4-(3-[l- hydroxy]ethyl)phenoxybutyrate. NMR
1.2 (t) 1.5H ethyl ester , 1.5 (d) 3H, 2.1 (m) 2H, 2.5 (m) 2H, 3.7 (s) 1.5H methyl ester, 4.0 (t) 2H, 4.1 (q) IH, ethyl ester, 4.9 (m) IH, 6.8 (d) IH, 6.9 (s) 2H, 7.2 (m) IH. d5) Alcohol for use in the Preparation of Compound No. 23
To 1,3 benzenedimethanol (1.4g) in THF (10ml) added t-butylacrylate (2g) followed by a 2 drops of benzyltrimethylammonium hydroxide solution. The mix stirred for lhr. , evaporated and purified by chromatography on silica using an increasingly polar mixture of hexane/ethyl aceate to give after evaporation of the appropriate fractions 0.55g of t-butyl (3- hydroxymethyl)benzyloxypropionate as an oil.
M+H 267
d61 Alcohol for use in the Preparation of Compound No. 35
To 4-hydroxypiperidine (2g) in DMf (35ml) was added potassium carbonate (8.2g) and methyl 4-bromobutyrate (2.9ml). The mix was stirred at 70C for 8hrs and then cooled, and partitioned between ethyl acetate and water, the organic layer washed with brine, dried and evaporated to dryness. The residue has a consistent M+H and was used without further purification or characterisation.
d7) Alcohol for use in the Preparation of Compound No. 41 To 4-(3-hydroxypropyl)pyridine (1.4g) in acetonitrile (10ml) was added t-butyl bromoacetate (2g) and the mixture allowed to stand for 24 hrs., and evaporated. The residue was dissolved in methanol and hydrogenated at atmospheric pressure in the presence of 10% palladium on carbon catalyst at 55C for 16 hrs. The mix was cooled, filtered and evaporated to give t-butyl 4-(3-hydroxypropyl)piperidinylacetate M+H 258
d8) Alcohol for use in the Preparation of Compound No. 43
To 4-(2-hydroxyethyl)piperidine (1.29g) in acetonitrile (5ml) was added t-butyl acrylate (1.28g) and the mixture allow to stand for 18hrs, evaporated to give t-butyl 4-(2- hydroxyethyl)piperidinylpropionate M+H 258
d9) Alcohol for use in the Preparation of Compound No. 25 To 3-(hydroxyethoxy)phenol (CAS49650-88-6) (1.54g) in N-methylpyrollidinone
(3ml) was added potassium carbonate (2.8g) and t-butylbromoacetate (1.95g) and the mix stirred for 18hrs, then added to a mixture of brine and diethyl ether. The organic layer was washed with brine, dried and evaporated to dryness and the residue purified by chromatography using an increasingly polar mixture of hexane / ethyl acetate to give t-butyl 3 -(hydroxy ethoxy)phenoxy acetate M+H 269
dlO) Alcohol for use in the Preparation of Compound No. 26 in Table 1
To methyl 4-iodophenylacetate (27g) in acetonitrile (300ml) were stirred and palladium chloride (0.17g), copper (I) iodide (0.37g), triphenylphosphine (0.5 lg) , 3-butyn-l - ol (8.85g ) and triethylamine (20ml) were added and the mixture stirred under an inert atmosphere in the absence of light for 18hrs. and then the solvent removed by evaporation and the residue partitoned between water and ethyl acetate, the organic layer removed, dried and evaporated to dryness. The residue was purified by chromatography on silica using an increasingly polar mixture of ethyl acetate/hexane. The appropriate fractions evaporated to dryness gave methyl 4-(4-hydroxybut-3-ynyl)phenylacetate (18.6g)
This was reduced in ethanol(250ml) using Pd/C catalyst (5%,2g) under an atmosphere of hydrogen gas at a pressure of 3 atmospheres for lhr, filtered and evaporated to dryness to give methyl 4-(4-hydroxybutyl)phenylacetate (18g) as a yellow oil used without further purification or characterisation.
Table 8
Example 9
The compounds of the invention or pharmaceutically acceptable salts thereof may be formulated into tablets together with, for example, lactose Ph.Eur, Croscarmellose sodium, maize starch paste (5% w/v paste) and magnesium stearate for therapeutic or prophylactic use in humans. The tablets may be prepared by conventional procedures well known in the pharmaceutical art and may be film coated with typical coating materials such as hydroxypropylmethylcellulose.
In Vitro and In Vivo Assays
The following abbreviations are used. Suitable sources of materials are listed below. MOLT-4 cells - human T-lymphoblastic leukaemia cells (European Collection of Animal Cell Cultures, Porton Down).
Fibronectin - purified from human plasma by gelatin-sepharose affinity chromatography according to the methods described in E.Nengvall, E.Ruoslahti, Int. J. Cancer, 1977, 20, pages 1-5 and J. Forsyth et al, Methods in Enzymology, 1992, 215, pages 31 1-316).
RPMI 1640 - cell culture medium. (Life technologies, Paisley UK). PBS - Dulbecco's phosphate buffered saline (Life Technologies). BSA - Bovine serum albumin, fraction V (ICN, Thame, UK). CFA - Complete Freund's Adjuvant (Life Technologies).
In the following assays and models references to compound(s) refers to the compounds of formula (I) according to the present invention. 1.1 In vitro assay : MOLT-4 cell/ Fibronectin adhesion assay.
The MOLT-4 cell /fibronectinadhesion assay was used to investigate the interaction of the integrin α4-β, expressed on the MOLT-4 cell membrane with fibronectin. Polystyrene 96 well plates were coated overnight at 4°C with fibronectin, 100 μl of 10 μg/ml in PBS. Nonspecific adhesion sites were blocked by adding 100 μl BSA, 20 mg/ml. After incubating for 1 h at room temperature, the solutions were aspirated. MOLT-4 cells suspended in serum-free RPMI-1640 medium 2E6 cells/ml (50 μl) and solutions of compound diluted in the same medium (50 μl) were added to each well. After incubation for 2 h at 37°C in a humidified atmosphere of 5% (v/v) CO2, non-adherent cells were removed by gentle shaking followed by vacuum aspiration. Adherent cells were quantified by a colorimetric acid phosphatase assay. To each well was added 100 μl p-nitrophenyl phosphate (6 mg/ml) in 50 mM sodium acetate buffer, pH 5.0, containing 1% Triton X-100. After incubation for 1 h at 37°C, 50 μl sodium hydroxide (1M) was added to each well and the absorbance 405 nm was measured on a microplate spectrophotometer. Compounds which inhibited adhesion gave a lower absorbance reading. Standard, control and test conditions were assayed in triplicate. Percentage inhibition was calculated with respect to total (no inhibitor) and non-specific (no fibronectin) standards on each plate.
1.2 In-vivo Inflammation Models
Activity of a compound can be tested in the following models. 1.2.1 Ovalbumin Delayed type Hypersensitivity in mice
Balb/c female mice (20-25g) are immunised on the flank with an 1 : 1 (v/v) emulsion of ovalbumin (2 mg/ml) with CFA. Seven days later the mice are challenged by subplantar injection of 1% heat aggregated ovalbumin in saline (30 μl) into the right hind foot pad. Swelling of the foot develops over a 24 hour period following which foot pad thickness is measured and compared with the thickness of the contralateral uninjected foot. The percentage increase in foot pad thickness is calculated. Compounds are dosed orally by gavage to groups of 5 mice at doses ranging from 0.001 mg/kg to 100 mg/kg. Inhibition of the inflammatory response is calculated comparing vehicle treated animals and compound treated groups. 1.2.2. Collagen-induced arthritis in mice
DBA/1 male mice are immunised with 0.1ml of an emulsion prepared from equal volumes of bovine collagen type II in 0.05M acetic acid (2 mg/ml) and CFA. This mixture is injected at the base of the tail. Twenty days later compounds are dosed orally by gavage at doses ranging from O.OOlmg/kg/day to 100 mg/kg/day. On the day following the first dose, each animal receives an intra-peritoneal booster injection of 0.1ml of collagen type II in acetic acid. The mice are assessed for the incidence and severity of arthritis in all four limbs for up to 28 days. Inhibition of arthritis is calculated by comparing vehicle treated and compound treated mice.

Claims

Claims:
A compound of formula (I)
wherein
A' is NH or NR6, where R6 is C,.6alkyl, C2.6alkenyl, C2.6alkanoyl or C^alkoxycarbonyl; B is oxygen or sulphur;
Y' is a linker group comprising an optionally substituted hydrocarbyl chain which is optionally interposed by one or more heteroatoms independently selected from oxygen, nitrogen and sulphur and/or by a monocyclic or bicyclic ring system; or linker group Y' and A' can be taken together to form a 5 to 7 membered heterocyclic ring, optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2_6alkenyl, C2.6alkynyl, C|.6alkoxy, C2_ 6alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C,.6 alkyl]amino and C2.6alkanoylamino; m is from 0 to 5; n is from 0 to 4; R1 and R4 are each independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl, C,.6alkanoyl, C2.6alkynyl, C,_6 alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,.6 alkylamino, di-[(C!.6)alkyl]amino, C2.6alkanoylamino, N-C,_6alkylcarbamoyl, Cμ6alkoxylcarbonyl, N,N-di-[(C,.6alkyl]carbamoyl, C,.4alkoxylC,.6alkyl, (CH2)tOH where t is 1 or 2, -CO2Ra and CONRaRD where Ra and Rb are independently hydrogen or C,.6 alkyl or one of R4 can be taken together with A to form a 5 to 7 membered heterocyclic ring optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C^alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C,.6 alkyl]amino and C2.6alkanoylamino; R2 and R3 are each independently selected from hydrogen, C,_6 alkyl, C,-3 alkanoyl or C,.6 alkoxycarbonyl; and R5 is an acidic functional group; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof.
2. A compound according to claim 1 wherein Y' is an alkylene chain which is interposed by a monocyclic ring system and/or a heteroatom.
3. A compound according to claim 1 wherein the group A' is orientated in the meta or para position with respect to the ureido group in formula (I), and most preferably A' is orientated para- to the ureido group in formula (I).
4. A compound according to claim 1 of formula (IA)
wherein
A is nitrogen or NR6, where R6 is C,.6alkyl, C2.6alkanoyl or CLe-alkoxycarbonyl; B is oxygen or sulphur;
Y is a linker group connecting group B to group R5 and containing up to 10 atoms where each atom is independently selected from carbon, oxygen, nitrogen and sulphur and may optionally comprise a monocyclic or bicyclic ring system or linker group Y and A can be taken together to form a 5 to 7 membered heterocyclic ring, optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2_ 6alkynyloxy, C,.6alkylamino, di-[C,_6 alkyljamino and C2.6alkanoylamino; m is from 0 to 5; n is from 0 to 4;
R1 and R4 are each independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl, C:.6alkanoyl, C2.6alkynyl, C,.6 alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,_6 alkylamino, di-[(C,.6)alkyl]amino, C2.6alkanoylamino, N-C^alkylcarbamoyl, C,.6alkoxylcarbonyl, N,N-di-[(C,.6alkyl]carbamoyl, C,.4alkoxylC,.6alkyl, (CH2),OH where t is 1 or 2, -CO2Ra and CONRaRb where Ra and Rb are independently hydrogen or C,.6 alkyl or one of R4 can be taken together with A to form a 5 to 7 membered heterocyclic ring optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C,.6 alkyl]amino and C2.6alkanoylamino; R2 and R1 are each independently selected from hydrogen, C,_6 alkyl, C,-, alkanoyl or C,.6 alkoxycarbonyl; and R5 is an acidic functional group; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof.
5. A compound according to any one of the preceding claims of formula (II)
wherein
A, B, R1 to R5, m and n are as defined in claim 4,
D and G are each independently C alkyl or C2.4 alkenyl and each carbon is optionally substituted with halogeno, hydroxy, amino, nitro, phenyl, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl, C,.6alkanoyl, C2.6alkynyl, C,_6 alkoxy,
C2.6alkenyloxy, C2.6alkynyloxy, C,_6 alkylamino, di-[(C,.6)alkyl]amino, C2.6alkanoylamino
N-C|.6alkylcarbamoyl, C,.6alkoxylcarbonyl, ^J,N-di-[(C,.6alkyl]carbamoyl, CMalkoxylC,.
6alkyl, (CH2),OH where r is 1 or 2, -CO2R7 and CONR7R8 where R7 and R8 are independently hydrogen or C,_6 alkyl, or D and A can be taken together to form a 5 to 7 membered ring, optionally substituted with up to 3 substituents independently selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2.6alkenyl, C,.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C,_6 alkyl]amino and C2.6alkanoylamino; E is phenyl or a monocyclic heterocycle both optionally substituted with up to 3 substituents selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl, C2.6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C|.6alkyl]amino, C2.6alkanoylamino, C3.6 alkenoyl- amino, C3.6alkynoylamino, C,.6alkoxycarbonyl, N-C,.6alkylcarbamoyl, N,N-di-[C,.6 alkyl]carbamoyl, C,.6alkanoyl, CMalkoxylC,.6alkyl, (CH2)sOH where s is 1 or 2, -CO2R9 and CONR9R10 where R9 and R10 are independently hydrogen or C,_6 alkyl or E and D can be taken together to form a bicyclic ring system, optionally substituted with up to 3 substituents selected from halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano, C,.6alkyl, C2.5alkenyl, C2. 6alkynyl, C,.6alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,.6alkylamino, di-[C,.6 alkyljamino and C2.6alkanoy lamino ;
F is selected from oxygen, sulphur, amino or CR"R12; p and q are each independently 0 or 1 ; R" and R12 are each independently selected from hydrogen, halogeno, hydroxy, amino, nitro, phenyl, trifluoromethyl, trifluoromethoxy, cyano, carboxy, carbamoyl, C,.6alkyl, C2.6alkenyl, C,.6alkanoyl, C2.6alkynyl, C,.6 alkoxy, C2.6alkenyloxy, C2.6alkynyloxy, C,.6 alkylamino, di-[(C|.6)alkyl]amino, C2.6alkanoylamino, N-C,.6alkylcarbamoyl, C^alkoxylcarbonyl, N,N-di-[(Cμ6alkyl]carbamoyl, Cl.4alkoxylC,.6alkyl, (CH2)uOH where u is 1 or 2, -CO2R'5 and CNNR15R16 where R15 and R16 are independently hydrogen or C,.6 alkyl with the proviso that not more than one ring system can be formed from taking together two groups from R4, A, D and E; or a pharmaceutically acceptable salt or in-vivo hydrolysable derivative thereof.
6. A compound according to claim 5 wherein E is phenyl or a monocyclic heterocycle.
7. A pharmaceutical composition which comprises a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof and a pharmaceutically acceptable carrier.
8. A compound according to any one of claims 1 to 6 for use in a method of therapeutic treatment of the human or animal body.
9. The use of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof in the production of a medicament for use in the treatment of a disease or medical condition mediated by the interaction between fibronectin and/or VCAM-1 (especially VCAM-1) and the integrin receptor α4β,
10. A process for preparing a compound of formula (I), a pharmaceutically acceptable salt or an in vivo hydrolysable derivative thereof which method comprises either
(a) reacting a compound of formula (IV)
where A', R', R2, R3, R4, m and n are as defined in relation to formula (I), with a compound of formula (V)
where B and Y' are as defined in relation to formula (I), Z is a leaving group, such as halo, and R'7 is a group R5 as defined in relation to formula (I) or a protected form thereof: or
(b) reacting a compound of formula (VI) where A', B, Y' R3, R4 and n are as defined in relation to formula (I) and R17 is as defined in relation to formula (V) with a compound of formula (VII)
where R1 and m are as defined in relation to formula (I); and thereafter if desired or necessary, i) removing any protecting groups; and. ii) optionally forming a pharmaceutically acceptable salt or in vivo hydrolysable derivative.
EP00920908A 1999-04-24 2000-04-19 Diphenylurea derivatives Withdrawn EP1173415A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9909409.6A GB9909409D0 (en) 1999-04-24 1999-04-24 Chemical compounds
GB9909409 1999-04-24
PCT/GB2000/001542 WO2000064866A1 (en) 1999-04-24 2000-04-19 Diphenylurea derivatives

Publications (1)

Publication Number Publication Date
EP1173415A1 true EP1173415A1 (en) 2002-01-23

Family

ID=10852165

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00920908A Withdrawn EP1173415A1 (en) 1999-04-24 2000-04-19 Diphenylurea derivatives

Country Status (5)

Country Link
EP (1) EP1173415A1 (en)
JP (1) JP2002543060A (en)
AU (1) AU4132000A (en)
GB (1) GB9909409D0 (en)
WO (1) WO2000064866A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001348D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
GB2369357A (en) * 2000-10-09 2002-05-29 Bayer Ag Aliphatic, cyclic amino carboxylic acids as integrin antagonists
DE10063173A1 (en) * 2000-12-18 2002-06-20 Merck Patent Gmbh Urea and urethane derivatives
DE602004000260T2 (en) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego DIARYL AND ARYLHETEROARYL DRUG DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR SUITABLE FOR THE PROPHYLAXIS AND TREATMENT OF RELATED DISEASES THEREOF
ATE548353T1 (en) 2004-03-23 2012-03-15 Arena Pharm Inc METHOD FOR PRODUCING SUBSTITUTED N-ARYL-N'-Ä3-(1H-PYRAZOLE-5-YL)PHENYLÜ-UREAS AND INTERMEDIATE THEREOF.
SA05260357B1 (en) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك 3-phenyle-pyrazole derivatives as modulators of the 5-ht 2a serotonin receptor useful for the treatment of disorders related thereto
CA2646076C (en) 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
SG171681A1 (en) 2006-05-18 2011-06-29 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
JP5406018B2 (en) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ， インコーポレイテッド Primary amines as modulators of 5-HT2A serotonin receptors useful for the treatment of disorders associated with 5-HT2A serotonin receptors, and derivatives thereof
TWI415845B (en) 2006-10-03 2013-11-21 Arena Pharm Inc Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JP5393677B2 (en) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド Imidazo [1,2-a] pyridine derivatives as modulators of 5-HT2A serotonin receptors for the treatment of disorders associated with 5-HT2A serotonin receptors
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
CA2741731A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US9839609B2 (en) 2009-10-30 2017-12-12 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (en) 2015-07-15 2018-09-04 Axovant Sciences Gmbh method for the prophylaxis and / or treatment of visual hallucinations in a subject in need
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
FI3873884T3 (en) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE-2,4-DIONE DERIVATIVES AS ALPHA-4-BETA-7 INTEGRIN INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
JP7189368B2 (en) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド Compounds for inhibition of alpha4beta7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CN114641466B (en) 2019-06-12 2025-09-30 诺瑟拉有限公司 Sulfonylurea derivatives and uses thereof
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
NZ333904A (en) * 1996-07-25 2000-06-23 Biogen Inc VLA-4 and IIb/IIIa cell adhesion inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0064866A1 *

Also Published As

Publication number Publication date
JP2002543060A (en) 2002-12-17
AU4132000A (en) 2000-11-10
GB9909409D0 (en) 1999-06-23
WO2000064866A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
WO2000064866A1 (en) Diphenylurea derivatives
EP1030835B1 (en) Urea derivatives and their use as integrin inhibitors
JP3555876B2 (en) N-aroylphenylalanine derivative
AU668733B2 (en) Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials
US6268365B1 (en) Src family SH2 domain inhibitors
JP4022142B2 (en) New compounds
JP2010208945A (en) Heterocyclic compound
SK45497A3 (en) Benzoxazoles, pharmaceutical composition containing them and their use
JP2003503350A (en) VLA-4 inhibitor compounds
JP2002521375A (en) Compound
KR20010043906A (en) A NOVEL VLA-4 INHIBITOR:oMePUPA-V
US7345063B2 (en) Amides, preparation and therapeutic use as modulators of CCR-receptor activity
US6441012B1 (en) Chemical compounds
EP0558677B1 (en) Biologically active amines
US20030181498A1 (en) Bicyclic heteroaryl compounds as inhibitors of the interaction between the integrin alpha4beta1 receptor and vcam-1 and/or fibronectin
US20030087956A1 (en) Urea compounds as inhibitors for vla-4
JP4528768B2 (en) N- (2-phenylethyl) sulfamide derivatives as integrin α4 antagonists
US5294638A (en) Phenyalkylaminoalkyl compounds and pharmaceutical compositions containing them
JP2010126496A (en) Heterocyclic compound
JP2006502107A (en) 2,5-Substituted pyrimidine derivatives as CCR-3 receptor antagonist IX
MXPA00004475A (en) Chemical compounds
JP2004519443A (en) Substituted pyrrolidines as CCR-3 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030327

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041127